<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Cancers (Basel)</journal-id>
<journal-id journal-id-type="iso-abbrev">Cancers (Basel)</journal-id>
<journal-id journal-id-type="publisher-id">cancers</journal-id>
<journal-title-group>
<journal-title>Cancers</journal-title>
</journal-title-group>
<issn pub-type="epub">2072-6694</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32151005</article-id>
<article-id pub-id-type="pmc">7139919</article-id>
<article-id pub-id-type="doi">10.3390/cancers12030604</article-id>
<article-id pub-id-type="publisher-id">cancers-12-00604</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Controversial Roles of ADP-Ribosyl Hydrolases MACROD1, MACROD2 and TARG1 in Carcinogenesis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8074-2180</contrib-id>
<name>
<surname>Feijs</surname>
<given-names>Karla L.H.</given-names>
</name>
<xref ref-type="aff" rid="af1-cancers-12-00604">1</xref>
<xref ref-type="corresp" rid="c1-cancers-12-00604">*</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9197-8041</contrib-id>
<name>
<surname>Cooper</surname>
<given-names>Christopher D.O.</given-names>
</name>
<xref ref-type="aff" rid="af2-cancers-12-00604">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Žaja</surname>
<given-names>Roko</given-names>
</name>
<xref ref-type="aff" rid="af1-cancers-12-00604">1</xref>
</contrib>
</contrib-group>
<aff id="af1-cancers-12-00604"><label>1</label>Institute of Biochemistry and Molecular Biology, RWTH Aachen University, Pauwelsstrasse 30, 52074 Aachen, Germany; <email>rzaja@ukaachen.de</email></aff>
<aff id="af2-cancers-12-00604"><label>2</label>Department of Biological and Geographical Sciences, School of Applied Sciences, University of Huddersfield, Queensgate, Huddersfield West Yorkshire HD3 4AP, UK; <email>c.d.cooper@hud.ac.uk</email></aff>
<author-notes>
<corresp id="c1-cancers-12-00604"><label>*</label>Correspondence: <email>kfeijs@ukaachen.de</email>; Tel.: +49-(241)-8080962</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>05</day>
<month>3</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<month>3</month>
<year>2020</year>
</pub-date>
<volume>12</volume>
<issue>3</issue>
<elocation-id>604</elocation-id>
<history>
<date date-type="received">
<day>15</day>
<month>1</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>27</day>
<month>2</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© 2020 by the authors.</copyright-statement>
<copyright-year>2020</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Post-translational modifications (PTM) of proteins are crucial for fine-tuning a cell’s response to both intracellular and extracellular cues. ADP-ribosylation is a PTM, which occurs in two flavours: modification of a target with multiple ADP-ribose moieties (poly(ADP-ribosyl)ation or PARylation) or with only one unit (MARylation), which are added by the different enzymes of the PARP family (also known as the ARTD family). PARylation has been relatively well-studied, particularly in the DNA damage response. This has resulted in the development of PARP inhibitors such as olaparib, which are increasingly employed in cancer chemotherapeutic approaches. Despite the fact that the majority of PARP enzymes catalyse MARylation, MARylation is not as well understood as PARylation. MARylation is a dynamic process: the enzymes reversing intracellular MARylation of acidic amino acids (MACROD1, MACROD2, and TARG1) were discovered in 2013. Since then, however, little information has been published about their physiological function. MACROD1, MACROD2, and TARG1 have a ‘macrodomain’ harbouring the catalytic site, but no other domains have been identified. Despite the lack of information regarding their cellular roles, there are a number of studies linking them to cancer. However, some of these publications oppose each other, some rely on poorly-characterised antibodies, or on aberrant localisation of overexpressed rather than native protein. In this review, we critically assess the available literature on a role for the hydrolases in cancer and find that, currently, there is limited evidence for a role for MACROD1, MACROD2, or TARG1 in tumorigenesis.</p>
</abstract>
<kwd-group>
<kwd>ADP-ribosylation</kwd>
<kwd>cancer</kwd>
<kwd>macrodomain</kwd>
<kwd>ADP-ribosyl hydrolase</kwd>
<kwd>PARP</kwd>
<kwd>ARTD</kwd>
<kwd>MACROD1</kwd>
<kwd>MACROD2</kwd>
<kwd>TARG1</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-cancers-12-00604">
<title>1. ADP-Ribosylation Reactions</title>
<p>Post-translational modifications of proteins can have a myriad of consequences: changing interactomes, stability, localisation, or activity are just a few examples. To date, more than 200 types of modification are known [<xref ref-type="bibr" rid="B1-cancers-12-00604">1</xref>]. The addition of ADP-ribose moieties to a protein was first reported in the 1960s when chains of (poly)ADP-ribose (PAR) were identified on target proteins, termed poly(ADP-ribosyl)ation (PARylation) [<xref ref-type="bibr" rid="B2-cancers-12-00604">2</xref>]. Since then, PARylation has been intensively studied, leading to the identification of crucial roles in the repair of DNA damage and to the development of specific inhibitors that are utilised in the clinic to treat diverse cancers [<xref ref-type="bibr" rid="B3-cancers-12-00604">3</xref>]. In contrast, much less is known about its smaller sibling, mono(ADP-ribosyl)ation (MARylation), where only single ADP-ribose units (MAR) are conjugated into proteins. In 2008, it was first noted that PARP10/ARTD10 has MARylation rather than PARylation activity [<xref ref-type="bibr" rid="B4-cancers-12-00604">4</xref>] and, lately, it has become clear that only the minority of PARP enzymes are capable of PARylation [<xref ref-type="bibr" rid="B5-cancers-12-00604">5</xref>]. Moreover, not only protein, but also DNA has been identified as a target for ADP-ribosylation catalysed by PARP3 [<xref ref-type="bibr" rid="B6-cancers-12-00604">6</xref>,<xref ref-type="bibr" rid="B7-cancers-12-00604">7</xref>]. Following PARP1 and PARP2, PARP3 has also been described as a potential therapeutic target in certain cancers [<xref ref-type="bibr" rid="B8-cancers-12-00604">8</xref>,<xref ref-type="bibr" rid="B9-cancers-12-00604">9</xref>,<xref ref-type="bibr" rid="B10-cancers-12-00604">10</xref>,<xref ref-type="bibr" rid="B11-cancers-12-00604">11</xref>]. The most recent addition to the spectrum of ADP-ribosylated molecules is RNA, which can be modified in vitro by multiple PARPs [<xref ref-type="bibr" rid="B12-cancers-12-00604">12</xref>].</p>
<p>One of the best-studied but still barely understood MARylating enzymes is PARP10. PARP10 was initially identified as an interactor of MYC [<xref ref-type="bibr" rid="B13-cancers-12-00604">13</xref>] and, later, of ubiquitinated proliferating cell nuclear antigen (PCNA) [<xref ref-type="bibr" rid="B14-cancers-12-00604">14</xref>,<xref ref-type="bibr" rid="B15-cancers-12-00604">15</xref>]. Its overexpression leads to cell death in HeLa cells through an unknown mechanism [<xref ref-type="bibr" rid="B16-cancers-12-00604">16</xref>]. In contrast, in non-transformed RPE-1 cells, overexpression leads to stimulation of cell growth [<xref ref-type="bibr" rid="B17-cancers-12-00604">17</xref>]. It has been given a role in replication and DNA damage [<xref ref-type="bibr" rid="B15-cancers-12-00604">15</xref>,<xref ref-type="bibr" rid="B17-cancers-12-00604">17</xref>,<xref ref-type="bibr" rid="B18-cancers-12-00604">18</xref>] as well as mitochondrial metabolism [<xref ref-type="bibr" rid="B19-cancers-12-00604">19</xref>], but it is not clear what the relevant substrates of this enzyme are. Potential substrates were identified using protein microarrays [<xref ref-type="bibr" rid="B20-cancers-12-00604">20</xref>], which was performed for the PARylating PARP2 [<xref ref-type="bibr" rid="B21-cancers-12-00604">21</xref>]. However, partially due to a lack of antibodies at that time, these modifications were not verified to occur in cells. PARP10 was also reported to be a regulator of NF-kB signaling [<xref ref-type="bibr" rid="B22-cancers-12-00604">22</xref>]. PARP14 functions as a co-activator of STAT6 and has been described as an anti-cancer and anti-inflammatory target, reviewed in more detail elsewhere [<xref ref-type="bibr" rid="B23-cancers-12-00604">23</xref>,<xref ref-type="bibr" rid="B24-cancers-12-00604">24</xref>]. PARP16 is located at the endoplasmic reticulum (ER) and plays a role in the unfolded protein response [<xref ref-type="bibr" rid="B25-cancers-12-00604">25</xref>,<xref ref-type="bibr" rid="B26-cancers-12-00604">26</xref>]. The most recent function identified for MARylation is its role in the anti-viral defence. PARP7, PARP10, and PARP12 gene expression is induced by interferon-α and ADP-ribosylation mediated by these PARPs may function to counteract viral proliferation [<xref ref-type="bibr" rid="B27-cancers-12-00604">27</xref>,<xref ref-type="bibr" rid="B28-cancers-12-00604">28</xref>]. In addition to enzymes of the PARP family, several sirtuins (SIRTs) appear to be able to ADP-ribosylate substrates in addition to their better-studied NAD<sup>+</sup>-dependent deacylase activity [<xref ref-type="bibr" rid="B29-cancers-12-00604">29</xref>,<xref ref-type="bibr" rid="B30-cancers-12-00604">30</xref>]. The first research showing that SIRTs possess MARylation activity described it as a very weak activity [<xref ref-type="bibr" rid="B31-cancers-12-00604">31</xref>]. Other papers, focusing on single enzymes, showed that the mitochondrial SIRT4 MARylates glutamate dehydrogenase to downregulate insulin secretion [<xref ref-type="bibr" rid="B32-cancers-12-00604">32</xref>]. The nuclear SIRT6 modifies PARP1 [<xref ref-type="bibr" rid="B33-cancers-12-00604">33</xref>] and BAF10 [<xref ref-type="bibr" rid="B34-cancers-12-00604">34</xref>] to regulate their activities and, lastly, the nucleolar SIRT7 was reported to MARylate histones p53 and ELK4 [<xref ref-type="bibr" rid="B35-cancers-12-00604">35</xref>]. To date, very little information is available about the MARylating activity of the SIRTs. The functional consequences of MARylation in normal cell physiology, thus, appear to be very diverse, reviewed extensively elsewhere [<xref ref-type="bibr" rid="B36-cancers-12-00604">36</xref>]. Herein, we focus on the enzymes reversing the intracellular MARylation reaction: the macrodomain-containing hydrolases.</p>
</sec>
<sec id="sec2-cancers-12-00604">
<title>2. Macrodomains</title>
<p>Intimately linked to ADP-ribosylation is a protein structural module known as the macrodomain, named for the unusually large histone macroH2A from which it was identified [<xref ref-type="bibr" rid="B37-cancers-12-00604">37</xref>]. The macrodomain is a protein fold formed around a central β-sheet, flanked by α-helices that forms a pocket where ADP-ribose can bind [<xref ref-type="bibr" rid="B38-cancers-12-00604">38</xref>,<xref ref-type="bibr" rid="B39-cancers-12-00604">39</xref>]. These pockets are slightly different between the macrodomain-containing proteins with the consequence that the macrodomain-containing protein family can be subdivided. Some macrodomains bind to PAR and others bind to MAR [<xref ref-type="bibr" rid="B40-cancers-12-00604">40</xref>,<xref ref-type="bibr" rid="B41-cancers-12-00604">41</xref>,<xref ref-type="bibr" rid="B42-cancers-12-00604">42</xref>,<xref ref-type="bibr" rid="B43-cancers-12-00604">43</xref>].</p>
<p>Macrodomains not only serve as binding modules to mediate protein interactions depending on ADP-ribosylation, but a number of them have catalytic activity. Poly(ADP-ribosyl)glycohydrolase (PARG) is able to degrade PAR chains by cleaving the glycosidic bond between adjacent ADP-ribose moieties. However, it cannot remove the final ADP-ribose attached to the protein [<xref ref-type="bibr" rid="B44-cancers-12-00604">44</xref>]. Three other proteins, MACROD1, MACROD2, and TARG1, are not active toward PAR but are capable of removing the ADP-ribose moiety connected to the protein partner, presumably by cleaving an ester bond between ADP-ribose and an acidic receptor amino acid [<xref ref-type="bibr" rid="B45-cancers-12-00604">45</xref>,<xref ref-type="bibr" rid="B46-cancers-12-00604">46</xref>,<xref ref-type="bibr" rid="B47-cancers-12-00604">47</xref>]. They can, therefore, both reverse any MARylation as generated by PARP enzymes, and also remove the last ADP-ribose left behind by PARG. Of the 12 human macrodomain-containing proteins known today, 11 proteins were identified by sequence homology [<xref ref-type="bibr" rid="B39-cancers-12-00604">39</xref>,<xref ref-type="bibr" rid="B43-cancers-12-00604">43</xref>]. The macrodomain of PARG was only recognised after the structure had been solved [<xref ref-type="bibr" rid="B44-cancers-12-00604">44</xref>], which indicates the possibility that more macrodomain-containing proteins remain to be identified. A recent bioinformatics approach has suggested that the largely uncharacterised protein C12orf4 harbours a macrodomain, or at least a macro-like domain, but this remains to be confirmed experimentally [<xref ref-type="bibr" rid="B48-cancers-12-00604">48</xref>].</p>
<p>The macrodomain is an evolutionary well-conserved module [<xref ref-type="bibr" rid="B39-cancers-12-00604">39</xref>]. For instance, recent work has shown that certain alpha-viruses encode a protein with a macrodomain-like fold [<xref ref-type="bibr" rid="B49-cancers-12-00604">49</xref>], which displays catalytic activity towards MARylated proteins [<xref ref-type="bibr" rid="B50-cancers-12-00604">50</xref>,<xref ref-type="bibr" rid="B51-cancers-12-00604">51</xref>,<xref ref-type="bibr" rid="B52-cancers-12-00604">52</xref>]. The existence of such proteins enhances the evidence connecting existing links between MARylation and immunity [<xref ref-type="bibr" rid="B53-cancers-12-00604">53</xref>]. In this review, we will focus specifically on potential oncogenic functions of the mono(ADP-ribosyl)hydrolases MACROD1, MACROD2, and TARG1. It should also be noted, however, that other macrodomain-containing proteins such as PARG and CHD1L (ALC1) have been previously linked closely to cancer [<xref ref-type="bibr" rid="B54-cancers-12-00604">54</xref>,<xref ref-type="bibr" rid="B55-cancers-12-00604">55</xref>]. </p>
</sec>
<sec id="sec3-cancers-12-00604">
<title>3. Macrodomain-Containing Hydrolases: MACROD1, MACROD2, and TARG1</title>
<p>MACROD1, MACROD2, and TARG1 are relatively small proteins (<xref ref-type="table" rid="cancers-12-00604-t001">Table 1</xref>) without any notable other domains beside the macrodomain. The first catalytic activity of MACROD1, MACROD2, and TARG1 that was recognised was their deacetylation of <italic>O-</italic>acetyl-ADP-ribose (<italic>O</italic>AADPR) to generate acetyl and ADP-ribose [<xref ref-type="bibr" rid="B56-cancers-12-00604">56</xref>,<xref ref-type="bibr" rid="B57-cancers-12-00604">57</xref>]. <italic>O</italic>AADPR arises as a by-product of SIRT-mediated deacetylation in which the acetyl group is transferred onto ADP-ribose while releasing nicotinamide, and may have important biological functions [<xref ref-type="bibr" rid="B58-cancers-12-00604">58</xref>]. Two years later, three labs reported the activity of MACROD1, MACROD2, and TARG1 in removing ADP-ribose from protein substrates, which was proposed to be limited to removal of ADP-ribose from acidic amino acids [<xref ref-type="bibr" rid="B43-cancers-12-00604">43</xref>,<xref ref-type="bibr" rid="B45-cancers-12-00604">45</xref>,<xref ref-type="bibr" rid="B46-cancers-12-00604">46</xref>,<xref ref-type="bibr" rid="B47-cancers-12-00604">47</xref>]. Serine and arginine MARylation were suggested to be removed by ARH3 and ARH1, respectively [<xref ref-type="bibr" rid="B59-cancers-12-00604">59</xref>,<xref ref-type="bibr" rid="B60-cancers-12-00604">60</xref>,<xref ref-type="bibr" rid="B61-cancers-12-00604">61</xref>,<xref ref-type="bibr" rid="B62-cancers-12-00604">62</xref>], which are structurally different proteins that do not contain a macrodomain. In 2017, MACROD1, MACROD2, and TARG1 were reported as being capable of removing ADP-ribose from both modified single-stranded DNA [<xref ref-type="bibr" rid="B63-cancers-12-00604">63</xref>] and, in 2018, also being capable of removing ADP-ribose from MARylated single-stranded RNA [<xref ref-type="bibr" rid="B12-cancers-12-00604">12</xref>]. Lastly, in 2019, the hydrolysis of α-NAD was added to the list of their in vitro activities [<xref ref-type="bibr" rid="B64-cancers-12-00604">64</xref>].</p>
<p>To date, it is not known which of these activities is relevant for their functionality in cells, either in normal physiology nor in pathological conditions. This is predominantly due to the fact that it is not well known how prevalent their in vitro substrates are in cells or what their cellular functions may be. This is partially due to the fact that antibodies or modules recognising MARylation have been developed only recently [<xref ref-type="bibr" rid="B65-cancers-12-00604">65</xref>,<xref ref-type="bibr" rid="B66-cancers-12-00604">66</xref>,<xref ref-type="bibr" rid="B67-cancers-12-00604">67</xref>]. Before these technical developments, it was not possible to confirm with antibodies that MARylation of proteins takes place in cells, and, hence, reversal mediated by these macrodomain-containing proteins could also not be assessed. Currently, it is still not straightforward to estimate endogenous MARylation levels in cells, as no inhibitors were available for MACROD1, MACROD2, or TARG1. During experimental procedures such as cell fixation or lysis, MARylation could possibly be removed by these enzymes and, therefore, go undetected. One study was performed to identify MACROD1 inhibitors using an AlphaScreen assay, where inhibitors in the micromolar range were identified. These can serve as lead compounds for further optimisation, but are likely not specific enough yet to be used for studies in cells due to their other activities at this concentration [<xref ref-type="bibr" rid="B68-cancers-12-00604">68</xref>]. Another study identified an allosteric inhibitor of macrodomain 2 of PARP14, which blocks its binding to ADP-ribose. However, it was not tested whether the identified compound might inhibit one of the macrodomains with catalytic activity [<xref ref-type="bibr" rid="B69-cancers-12-00604">69</xref>].</p>
<p>The roles of MACROD1, MACROD2, and TARG1 in normal cell biological processes are not well understood. They appear to be expressed and localised in different tissues and intracellular locations, which clearly gives them unique roles to play despite their biochemical similarity. This also explains why loss of TARG1 alone can lead to a neurodegenerative phenotype [<xref ref-type="bibr" rid="B45-cancers-12-00604">45</xref>]. MACROD1 resides in mitochondria [<xref ref-type="bibr" rid="B40-cancers-12-00604">40</xref>,<xref ref-type="bibr" rid="B70-cancers-12-00604">70</xref>,<xref ref-type="bibr" rid="B71-cancers-12-00604">71</xref>], but, depending on the tag used for overexpression, will reside exclusively in the nucleus instead [<xref ref-type="bibr" rid="B70-cancers-12-00604">70</xref>]. MACROD2 displays a more diffuse cytoplasmic/nuclear distribution [<xref ref-type="bibr" rid="B70-cancers-12-00604">70</xref>,<xref ref-type="bibr" rid="B75-cancers-12-00604">75</xref>] and overexpressed TARG1 appears to be present in nucleoplasm, nucleoli, and cytoplasmic stress granules [<xref ref-type="bibr" rid="B14-cancers-12-00604">14</xref>,<xref ref-type="bibr" rid="B70-cancers-12-00604">70</xref>]. TARG1 and MACROD1 are expressed throughout the different tissues with an enrichment of MACROD1 in skeletal muscle at both the protein and RNA level [<xref ref-type="bibr" rid="B70-cancers-12-00604">70</xref>]. MACROD2 has, thus far, only been detected in human neuroblastoma cells and in mouse cortical neurons [<xref ref-type="bibr" rid="B70-cancers-12-00604">70</xref>,<xref ref-type="bibr" rid="B76-cancers-12-00604">76</xref>]. Several reports have correlated polymorphisms or deletions within the <italic>MACROD2</italic> gene with autism-spectrum disorders [<xref ref-type="bibr" rid="B77-cancers-12-00604">77</xref>,<xref ref-type="bibr" rid="B78-cancers-12-00604">78</xref>,<xref ref-type="bibr" rid="B79-cancers-12-00604">79</xref>,<xref ref-type="bibr" rid="B80-cancers-12-00604">80</xref>]. It is not clear, however, whether the <italic>MACROD2</italic> gene product itself or surrounding genes are responsible for this association even though elevated protein expression in neurons supports a potential brain-specific function of MACROD2 [<xref ref-type="bibr" rid="B76-cancers-12-00604">76</xref>]. However, a long non-coding RNA has been identified within an intron of the <italic>MACROD2</italic> gene, which is more highly expressed in most tissues investigated than the <italic>MACROD2</italic> mRNA, and, thereby, potentially confuses correlations of mutations in the <italic>MACROD2</italic> gene and phenotypes [<xref ref-type="bibr" rid="B81-cancers-12-00604">81</xref>]. In another genome-wide association study, <italic>MACROD2</italic> was identified as a factor influencing vascular-adhesion protein-1 (VAP-1) levels, which the authors confirmed by knockdown of MACROD2. This leads to lower VAP-1 expression in adipocytes, presumably through the transcriptional regulation of VAP-1 [<xref ref-type="bibr" rid="B82-cancers-12-00604">82</xref>]. MACROD2 was also reported to leave the nucleus upon DNA damage, dependent on phosphorylation by ATM [<xref ref-type="bibr" rid="B75-cancers-12-00604">75</xref>], whereas TARG1 localises from nucleoli to nuclear sites of damage [<xref ref-type="bibr" rid="B14-cancers-12-00604">14</xref>], which both have an unclear functional relevance. More data may be found on MACROD1, which is also known as leukaemia-related protein 16 or LRP16. MACROD1 has been attributed to a number of functions in the nucleus, such as co-activation of the androgen receptor [<xref ref-type="bibr" rid="B83-cancers-12-00604">83</xref>], counteracting PARP7-mediated MARylation in the nucleus [<xref ref-type="bibr" rid="B84-cancers-12-00604">84</xref>,<xref ref-type="bibr" rid="B85-cancers-12-00604">85</xref>], and activation of NF-kB signalling [<xref ref-type="bibr" rid="B86-cancers-12-00604">86</xref>,<xref ref-type="bibr" rid="B87-cancers-12-00604">87</xref>,<xref ref-type="bibr" rid="B88-cancers-12-00604">88</xref>]. MACROD1 was also reported as an enhancer of oestrogen receptor signalling [<xref ref-type="bibr" rid="B89-cancers-12-00604">89</xref>], and is upregulated after stimulation of cells with oestrogen [<xref ref-type="bibr" rid="B72-cancers-12-00604">72</xref>,<xref ref-type="bibr" rid="B74-cancers-12-00604">74</xref>,<xref ref-type="bibr" rid="B90-cancers-12-00604">90</xref>]. No regulatory factors have been identified yet for MACROD2 and TARG1. A BioID interaction screen, which identifies proteins in close proximity to the protein of interest [<xref ref-type="bibr" rid="B91-cancers-12-00604">91</xref>], identified many proteins involved in nuclear/cytoplasmic and mitochondrial nucleic acid metabolism as interactors of TARG1 and MACROD1, respectively [<xref ref-type="bibr" rid="B70-cancers-12-00604">70</xref>]. Whether these proteins are MARylated and serve as a substrate of TARG1/MACROD1 remains to be determined. It is possible that, despite spatio-temporal restrictions, MACROD1 and TARG1 in their respective compartments are involved in similar signalling networks, converging on the regulation of cellular nucleic acids. The physiological functions of the three enzymes remains elusive. Most puzzling perhaps is that, at the moment, despite the mitochondrial localisation of MACROD1, the majority of reports describe nuclear functions. Future work will need to address this apparent discrepancy.</p>
</sec>
<sec id="sec4-cancers-12-00604">
<title>4. Mono(ADP-ribosyl)ation in Cancer</title>
<p>The post-translational modification poly(ADP-ribosyl)ation has been intimately linked to cancer before [<xref ref-type="bibr" rid="B92-cancers-12-00604">92</xref>,<xref ref-type="bibr" rid="B93-cancers-12-00604">93</xref>], as have other post-translational modifications such as phosphorylation [<xref ref-type="bibr" rid="B94-cancers-12-00604">94</xref>]. In BRCA1/BRCA2-deficient patients, PARP1 inhibitors have been shown effective specifically against the tumour cells applied in the clinic. However, this is one of the rare examples of a synthetic lethal interaction [<xref ref-type="bibr" rid="B95-cancers-12-00604">95</xref>]. Better understanding of the processes regulated by MARylation will provide opportunities for further drug development, as is exemplified by current research into the potential of PARP14 as a drug target [<xref ref-type="bibr" rid="B24-cancers-12-00604">24</xref>]. Little is known about the potential role of the mono(ADP-ribosyl)hydrolases in cancer. <italic>MACROD1</italic>, <italic>MACROD2</italic>, and <italic>OARD1</italic> (TARG1) exhibit mutations only in 0.9%, 2.6%, and 1% of cancer patient samples, respectively, from over 1000 samples in the cBioPortal curated dataset [<xref ref-type="bibr" rid="B96-cancers-12-00604">96</xref>]. The fact that <italic>MACROD2</italic> mutation rates are twice the rates seen for <italic>MACROD1</italic> and <italic>OARD1</italic> likely reflects that the <italic>MACROD2</italic> gene is larger (<xref ref-type="fig" rid="cancers-12-00604-f001">Figure 1</xref>), and is located at a known fragile region [<xref ref-type="bibr" rid="B97-cancers-12-00604">97</xref>]. A specific recurring deletion of exon 6 has been observed in esophageal squamous cell carcinoma and gastric cancer [<xref ref-type="bibr" rid="B98-cancers-12-00604">98</xref>]. For <italic>MACROD1</italic>, a <italic>RUNX-MACROD1</italic> fusion was identified in leukaemia [<xref ref-type="bibr" rid="B99-cancers-12-00604">99</xref>] and, for <italic>MACROD2</italic>, a <italic>PDGFRA-MACROD2</italic> fusion in a pleomorphic sarcoma [<xref ref-type="bibr" rid="B100-cancers-12-00604">100</xref>]. Despite the low number of identified mutations in patient tumour samples, several reports have correlated <italic>MACROD1</italic> or <italic>MACROD2</italic> expression levels with the clinical outcome, as described in the next paragraphs.</p>
<p>The gene structure of <italic>MACROD1</italic>, <italic>MACROD2</italic>, and <italic>OARD1</italic> is shown schematically. More lncRNAs are present. However, only RPS10P2-201 is displayed since it has been shown to be relevant RPS10P2-201 [<xref ref-type="bibr" rid="B81-cancers-12-00604">81</xref>]. CDS = coding sequence. UTR = untranslated region.</p>
</sec>
<sec id="sec5-cancers-12-00604">
<title>5. MACROD1 in Cancer</title>
<p>A number of studies have addressed a potential oncogenic function of MACROD1 and started deciphering the molecular mechanism underlying observed effects. MACROD1 expression was shown to be upregulated by oestrogen [<xref ref-type="bibr" rid="B73-cancers-12-00604">73</xref>,<xref ref-type="bibr" rid="B74-cancers-12-00604">74</xref>], which leads to several studies of the role of MACROD1 in tumours with a differential oestrogen status. MACROD1 overexpression in the oestrogen and progesterone receptor positive Ishikawa cells, derived from an endometrial cancer, had no effect on cell proliferation. It did, however, enhance the invasiveness of these cells as measured by transwell assays [<xref ref-type="bibr" rid="B101-cancers-12-00604">101</xref>]. Mechanistically, the authors propose a mechanism wherein MACROD1, dependent on oestrogen, blocks recruitment of ERα to the E-cadherin promoter, which lowers E-cadherin expression and, through this, enhances invasiveness. shRNA-mediated knockdown of MACROD1 achieved the opposite effect by enhancing E-cadherin expression [<xref ref-type="bibr" rid="B101-cancers-12-00604">101</xref>]. This implies that MACROD1 can be an important factor in metastasis. These findings appear to contradict an earlier report where overexpression of MACROD1 in MCF7 cells, which are oestrogen-responsive breast cancer cells, showed an effect on cell growth. It led to enhanced proliferation [<xref ref-type="bibr" rid="B74-cancers-12-00604">74</xref>]. A later report studying MACROD1 in 293T cells showed that knockdown of MACROD1 sensitized cells to TNFα-induced apoptosis [<xref ref-type="bibr" rid="B86-cancers-12-00604">86</xref>]. From these studies, it is, thus, not clear what effect loss or gain of MACROD1 has on cell physiology. Recent work has demonstrated that fusing an N-terminal tag, such as GFP, to MACROD1 leads to a nuclear localisation, whereas C-terminally labelled and an endogenous protein appear to be exclusively localised in mitochondria [<xref ref-type="bibr" rid="B70-cancers-12-00604">70</xref>]. Mass spectrometry datasets have also detected MACROD1 in the mitochondria [<xref ref-type="bibr" rid="B102-cancers-12-00604">102</xref>]. This does not exclude the possibility that, under specific circumstances, MACROD1 may re-localise to the nucleus. In pathogenic conditions, such as the presence of a <italic>RUNX-MACROD1</italic> fusion protein that was identified in leukaemia [<xref ref-type="bibr" rid="B99-cancers-12-00604">99</xref>], the protein likely also localises to the nucleus instead of the mitochondria, as the RUNX fusion will mask the mitochondrial targeting sequence, comparable to the localisation after labelling with an N-terminal GFP tag. Unfortunately, some of the studies investigating MACROD1 have either used N-terminally tagged fusion constructs [<xref ref-type="bibr" rid="B84-cancers-12-00604">84</xref>,<xref ref-type="bibr" rid="B85-cancers-12-00604">85</xref>,<xref ref-type="bibr" rid="B88-cancers-12-00604">88</xref>], or have not stated clearly how the fusion proteins were generated [<xref ref-type="bibr" rid="B103-cancers-12-00604">103</xref>]. Furthermore, the majority of applied antibodies show multiple bands in the western blot and, hence, are not suitable for immunohistochemistry (IHC) or immunofluorescence (IF) (<xref ref-type="table" rid="cancers-12-00604-t002">Table 2</xref>). It will be worthwhile to repeat some of the studies of MACROD1′s molecular function in carcinogenesis to clarify whether unlabeled MACROD1 overexpression leads to enhanced cell growth, or whether this effect depends on the tumour background and also to study knockdown/knockout systems more thoroughly.</p>
<p>Despite these technical challenges, multiple studies have correlated tumour growth with MACROD1 expression in either xenograft models or in patient cohorts. Overexpression of MACROD1 in the hepatocellular carcinoma lines HepG2 and MHCC-97L leads to a decrease in cell growth and metastatic potential, as measured by transwell assays [<xref ref-type="bibr" rid="B103-cancers-12-00604">103</xref>]. Furthermore, when delivered into nude mice, cells overexpressing MACROD1 lead to a decreased tumour volume and have a lower metastatic potential compared to cells without overexpressed MACROD1 [<xref ref-type="bibr" rid="B103-cancers-12-00604">103</xref>]. With the information available, it cannot be distinguished whether this is a genuine effect or an artefact due to forced nuclear localisation of the overexpression construct [<xref ref-type="bibr" rid="B103-cancers-12-00604">103</xref>]. In a similar set of experiments in the pancreatic carcinoma cell lines, Panc1, CFPAC1, Bxpc3, SW1990, AsPC1, and HPDE6-C7, opposite results were achieved [<xref ref-type="bibr" rid="B105-cancers-12-00604">105</xref>]. Knockdown of MACROD1 leads to enhanced apoptosis and decreased cell growth. However, only one shRNA construct was used, so any effects seen could be potentially off-target. Cells overexpressing the same MACROD1 construct as in the study described before [<xref ref-type="bibr" rid="B103-cancers-12-00604">103</xref>] grew faster and were more resistant to apoptosis. Xenograft experiments show the same trend. Cells lacking MACROD1 had a lower tumour-forming potential and higher survival rate. Cells overexpressing MACROD1 had a higher tumour volume and a lower survival rate [<xref ref-type="bibr" rid="B105-cancers-12-00604">105</xref>]. The authors do not comment on the opposing effects in these two tumour types, but agree that larger-scale studies are required to verify these findings. A third study shows IHC of lung tumour samples with an antibody of an unknown source and specificity [<xref ref-type="bibr" rid="B104-cancers-12-00604">104</xref>]. High MACROD1 expression, as measured by IHC, was reported to correlate with a negative outcome in colorectal carcinoma and in gastric carcinoma. However, the antibody used was generated by the authors and not validated by a western blot [<xref ref-type="bibr" rid="B106-cancers-12-00604">106</xref>,<xref ref-type="bibr" rid="B107-cancers-12-00604">107</xref>]. CRISPR-mediated <italic>MACROD1</italic> knockout rhabdomyosarcoma cells [<xref ref-type="bibr" rid="B70-cancers-12-00604">70</xref>] and <italic>MACROD1</italic> knockout mice appear viable [<xref ref-type="bibr" rid="B71-cancers-12-00604">71</xref>], which makes it unlikely that loss of MACROD1 has a drastic growth inhibitory or developmental effect.</p>
<p>In conclusion, most of the data available on an oncogenic function of MACROD1 rely on poorly characterised antibodies, unclear overexpression constructs or a single shRNA construct. The majority of these studies would need to be reproduced with a more thorough characterisation and description of the materials used to be able to draw deeper conclusions. Several studies agree that MACROD1 expression can be induced by oestrogen [<xref ref-type="bibr" rid="B73-cancers-12-00604">73</xref>,<xref ref-type="bibr" rid="B74-cancers-12-00604">74</xref>,<xref ref-type="bibr" rid="B89-cancers-12-00604">89</xref>,<xref ref-type="bibr" rid="B90-cancers-12-00604">90</xref>,<xref ref-type="bibr" rid="B101-cancers-12-00604">101</xref>], but it remains unclear what the effect of this overexpression is on cells. The <italic>RUNX-MACROD1</italic> fusion identified in leukaemia may provide an important hint at a potential pathologic function. It is possible that the physiological mitochondrial localisation of MACROD1 can turn into a pathogenic nuclear one, where it aberrantly acts as a transcriptional activator. It will be interesting to see whether more instances can be identified where such fusions are present. Alternatively, other masking events may occur in cells, such as binding by interaction partners or PTMs, which, thereby, redirects the protein to the nucleus for a physiological function.</p>
</sec>
<sec id="sec6-cancers-12-00604">
<title>6. MACROD2 in Cancer</title>
<p>A number of analyses suggest MACROD2 may play a potential role in cancer. MACROD2 copy number is increased in three different tamoxifen-resistant MCF7 breast cancer cell lines, prompting the authors to analyse MACROD2 expression in patient samples. In oestrogen receptor-positive tissues of breast cancer patients with a recorded tamoxifen-resistance, however, three patients displayed a decreased copy number, whereas the other two patients showed an increase. Using IHC with a custom antibody, varying levels of MACROD2 were detected in primary and secondary tumour tissues of these patients, collectively showing that MACROD2 may be overexpressed in cancer tissues. MCF7 and T47D cells with exogenously overexpressed MACROD2 grow faster than control cells in media containing tamoxifen, which implies that MACROD2 confers tamoxifen-resistance to the cells and appear to be stimulated by tamoxifen, as demonstrated by faster growth in medium with tamoxifen than without [<xref ref-type="bibr" rid="B110-cancers-12-00604">110</xref>]. Conversely, tamoxifen-resistant MCF7 clones with shRNA-mediated knockdown of MACROD2 become more sensitive even though it does not completely reverse resistance [<xref ref-type="bibr" rid="B110-cancers-12-00604">110</xref>]. This may be mediated by the activation of oestrogen-regulated genes in response to tamoxifen in cells overexpressing MACROD2. Lastly, cells stably expressing shRNA to knockdown MACROD2 grow markedly slower in nude mice [<xref ref-type="bibr" rid="B110-cancers-12-00604">110</xref>]. The authors argue that, as a cancer specific fragile site, the MACROD2 gene can be lost, but this fragility also allows for amplification in the specific case of ER-positive breast cancers treated with tamoxifen to incur resistance. A more recent study showed that, in approximately one-third of colorectal carcinomas investigated, heterozygous or homozygous losses were mapped within the <italic>MACROD2</italic> gene in which the majority are intragenic microdeletions mapping to a region in exons 4 to 5 [<xref ref-type="bibr" rid="B111-cancers-12-00604">111</xref>]. To test whether MACROD2 deficiency can promote tumourigenesis, <italic>MACROD2</italic> knockout was introduced into an adenomatous polyposis coli protein (Apc) mouse model. Mutations in the APC tumour suppressor are a major driver of sporadic colorectal cancers, where it could be shown that even haploinsufficiency of <italic>MACROD2</italic> leads to more and larger adenoma formation [<xref ref-type="bibr" rid="B111-cancers-12-00604">111</xref>]. Furthermore, human cells transplanted into nude mice displayed increased tumour growth when lacking <italic>MACROD2</italic>, but a reduced tumour growth when MACROD2 was overexpressed [<xref ref-type="bibr" rid="B111-cancers-12-00604">111</xref>]. The underlying mechanism was suggested to be impaired PARP1 activity in the <italic>MACROD2</italic><sup>-/-</sup> cells, which leads to increased sensitivity of DNA damage and, ultimately, causes enhanced chromosomal instability [<xref ref-type="bibr" rid="B111-cancers-12-00604">111</xref>,<xref ref-type="bibr" rid="B112-cancers-12-00604">112</xref>].</p>
<p>These findings appear paradoxical with the previous report, where loss of MACROD2 impairs cell growth from a loss of resistance to tamoxifen. <italic>MacroD2</italic> knockout mice do not show altered survival rates after sub-lethal irradiation compared to wildtype mice, which indicates that loss of MACROD2 alone is not sufficient to drive tumourigenesis triggered by DNA damage [<xref ref-type="bibr" rid="B109-cancers-12-00604">109</xref>]. It is not clear whether loss or overexpression of MACROD2 contributes to tumourigenesis, or whether both can drive tumour growth dependent on conditions, such as the functionality of the DNA damage repair systems or the oestrogen receptor status. In an investigation of stage-III colon cancer, MACROD2 expression determined by immunohistochemistry was found to correlate with poor survival [<xref ref-type="bibr" rid="B113-cancers-12-00604">113</xref>]. A human protein atlas antibody (HPA049076) was used for this work, which has been retracted by the company in the meantime and did not appear to be validated in any way, such as western blotting or siRNA-mediated knockdown. It is, thus, not clear whether this antibody recognises MACROD2 at all, or whether it recognises additional proteins, which may be upregulated in the samples analysed. Altogether, it appears that loss of MACROD2 as such is not sufficient to drive tumourigenesis, but may have an additive effect in models prone to tumour formation such as loss of APC in colorectal cells. More studies are urgently needed to clarify the exact role of MACROD2 in both the onset of cancer as well as in the response of existing tumours to therapies.</p>
</sec>
<sec id="sec7-cancers-12-00604">
<title>7. TARG1 in Cancer</title>
<p>The only phenotype associated with TARG1 expression is neurodegeneration, occurring due to a mutation that leads to a truncated protein with a disrupted macrodomain, and, thereby, loss of catalytic activity [<xref ref-type="bibr" rid="B45-cancers-12-00604">45</xref>]. It is not clear whether this neurodegeneration is a result of a potentially toxic truncated or unfolded protein or from loss of hydrolase activity. Knockdown of TARG1 leads to a decrease in 293T cell proliferation and a slight increase in senescence in U2OS cells, which are derived from an osteosarcoma [<xref ref-type="bibr" rid="B45-cancers-12-00604">45</xref>]. CRISPR-mediated knockdown of TARG1 does not influence HeLa or U2OS proliferation [<xref ref-type="bibr" rid="B14-cancers-12-00604">14</xref>,<xref ref-type="bibr" rid="B70-cancers-12-00604">70</xref>], which leaves it unclear in which setting TARG1 is required for cell growth. Overexpression does not lead to changes in cell proliferation [<xref ref-type="bibr" rid="B14-cancers-12-00604">14</xref>,<xref ref-type="bibr" rid="B70-cancers-12-00604">70</xref>]. We could not identify any data linking TARG1 to cancer, nor see elevated expression or mutation in databases such as COSMIC. Based on expression levels in databases and these experimental results, at this stage, it does appear unlikely that TARG1 is involved in cancer even though further experimentation is required.</p>
</sec>
<sec id="sec8-cancers-12-00604" sec-type="conclusions">
<title>8. Conclusions</title>
<p>Despite the presence of several publications reporting a correlation between MACROD1 or MACROD2 levels and cancer development or progression, it is not clear at the moment that they have a causative role. MACROD2 is potentially relevant in ER-positive, tamoxifen resistant breast cancers where it may confer resistance to treatment. However, larger cohorts of patient samples need to be analysed to further substantiate these initial findings. Loss of <italic>MACROD2</italic> in an APC null background potentially stimulates tumour formation. However, loss of <italic>MacroD2</italic> alone does not have any effect in a knockout mouse model. Detailed studies are required to determine how loss of MACROD2 might cooperate with loss of APC to drive cancer. MACROD1 levels are upregulated by oestrogen with unclear consequences for cells. Yet, it may down-regulate E-cadherin and, thereby, promote metastasis. If confirmed, this may be an attractive therapeutic target intending to keep the cancer dormant and prevent metastasis.</p>
<p>Conflicting data show that overexpression and knockdown of MACROD1 have no effect, no stimulus, and no inhibition of cell growth, which implies that, perhaps, inhibiting MACROD1 may not have detrimental effects for the whole organism but rather may be dependent on the tumour background and, thus, may represent a valid drug target. The effects observed may, however, be dependent on the constructs used as well as on the specific cell-types and have to be studied in more detail. Future work will have to dissect in which context loss or gain of MACROD1 may be driving aspects of cancer growth. The recent development and characterisation of more specific antibodies, the ongoing improvements of mass spectrometric measurements of MARylation, and also the attempts at making specific inhibitors for both transferases and hydrolases should allow a more detailed analysis of their (patho-)physiological function in the near future. The partially paradoxical findings described will undoubtedly be clarified with better validated tools to determine the extent to which MACROD1, MACROD2, and TARG1 are relevant for tumourigenesis in order to establish their potential as drug candidates.</p>
</sec>
</body>
<back>
<notes>
<title>Author Contributions</title>
<p>Writing, review, and editing: K.L.H.F., C.D.O.C., and R.Ž. All authors have read and agreed to the published version of the manuscript.</p>
</notes>
<notes>
<title>Funding</title>
<p>The START Program of the Medical Faculty, RWTH Aachen University to K.L.H.F. (10/18) and to R.Z (13/20) funded this research.</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare no conflict of interest.</p>
</notes>
<ref-list>
<title>References</title>
<ref id="B1-cancers-12-00604">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Minguez</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Letunic</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Parca</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Garcia-Alonso</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Dopazo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Huerta-Cepas</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bork</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>PTMcode v2: A resource for functional associations of post-translational modifications within and between proteins</article-title>
<source/>Nucleic Acids Res.
          <year>2015</year>
<volume>43</volume>
<fpage>D494</fpage>
<lpage>D502</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gku1081</pub-id>
<pub-id pub-id-type="pmid">25361965</pub-id>
</element-citation>
</ref>
<ref id="B2-cancers-12-00604">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Virag</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>50 years of poly(ADP-ribosyl)ation</article-title>
<source/>Mol. Asp. Med.
          <year>2013</year>
<volume>34</volume>
<fpage>1043</fpage>
<lpage>1045</lpage>
<pub-id pub-id-type="doi">10.1016/j.mam.2013.05.002</pub-id>
<pub-id pub-id-type="pmid">23727362</pub-id>
</element-citation>
</ref>
<ref id="B3-cancers-12-00604">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Slade</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>PARP and PARG inhibitors in cancer treatment</article-title>
<source/>Genes Dev.
          <year>2020</year>
<pub-id pub-id-type="doi">10.1101/gad.334516.119</pub-id>
<pub-id pub-id-type="pmid">32029455</pub-id>
</element-citation>
</ref>
<ref id="B4-cancers-12-00604">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kleine</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Poreba</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Lesniewicz</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hassa</surname>
<given-names>P.O.</given-names>
</name>
<name>
<surname>Hottiger</surname>
<given-names>M.O.</given-names>
</name>
<name>
<surname>Litchfield</surname>
<given-names>D.W.</given-names>
</name>
<name>
<surname>Shilton</surname>
<given-names>B.H.</given-names>
</name>
<name>
<surname>Luscher</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Substrate-Assisted catalysis by PARP10 limits its activity to mono-ADP-ribosylation</article-title>
<source/>Mol. Cell
          <year>2008</year>
<volume>32</volume>
<fpage>57</fpage>
<lpage>69</lpage>
<pub-id pub-id-type="doi">10.1016/j.molcel.2008.08.009</pub-id>
<pub-id pub-id-type="pmid">18851833</pub-id>
</element-citation>
</ref>
<ref id="B5-cancers-12-00604">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vyas</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Matic</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Uchima</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rood</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zaja</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hay</surname>
<given-names>R.T.</given-names>
</name>
<name>
<surname>Ahel</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Family-Wide analysis of poly(ADP-ribose) polymerase activity</article-title>
<source/>Nat. Commun.
          <year>2014</year>
<volume>5</volume>
<fpage>4426</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms5426</pub-id>
<pub-id pub-id-type="pmid">25043379</pub-id>
</element-citation>
</ref>
<ref id="B6-cancers-12-00604">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Belousova</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Ishchenko</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Lavrik</surname>
<given-names>O.I.</given-names>
</name>
</person-group>
<article-title>DNA is a New Target of Parp3</article-title>
<source/>Sci. Rep.
          <year>2018</year>
<volume>8</volume>
<fpage>4176</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-018-22673-3</pub-id>
<pub-id pub-id-type="pmid">29520010</pub-id>
</element-citation>
</ref>
<ref id="B7-cancers-12-00604">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zarkovic</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Belousova</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Talhaoui</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Saint-Pierre</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kutuzov</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Matkarimov</surname>
<given-names>B.T.</given-names>
</name>
<name>
<surname>Biard</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gasparutto</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lavrik</surname>
<given-names>O.I.</given-names>
</name>
<name>
<surname>Ishchenko</surname>
<given-names>A.A.</given-names>
</name>
</person-group>
<article-title>Characterization of DNA ADP-ribosyltransferase activities of PARP2 and PARP3: New insights into DNA ADP-ribosylation</article-title>
<source/>Nucleic Acids Res.
          <year>2018</year>
<volume>46</volume>
<fpage>2417</fpage>
<lpage>2431</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkx1318</pub-id>
<pub-id pub-id-type="pmid">29361132</pub-id>
</element-citation>
</ref>
<ref id="B8-cancers-12-00604">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodriguez-Vargas</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Nguekeu-Zebaze</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Dantzer</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>PARP3 comes to light as a prime target in cancer therapy</article-title>
<source/>Cell Cycle
          <year>2019</year>
<volume>18</volume>
<fpage>1295</fpage>
<lpage>1301</lpage>
<pub-id pub-id-type="doi">10.1080/15384101.2019.1617454</pub-id>
<pub-id pub-id-type="pmid">31095444</pub-id>
</element-citation>
</ref>
<ref id="B9-cancers-12-00604">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beck</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rodriguez-Vargas</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Boehler</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Robert</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Heyer</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Hanini</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Gauthier</surname>
<given-names>L.R.</given-names>
</name>
<name>
<surname>Tissier</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schreiber</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Elofsson</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PARP3, a new therapeutic target to alter Rictor/mTORC2 signaling and tumor progression in BRCA1-associated cancers</article-title>
<source/>Cell Death Differ.
          <year>2019</year>
<volume>26</volume>
<fpage>1615</fpage>
<lpage>1630</lpage>
<pub-id pub-id-type="doi">10.1038/s41418-018-0233-1</pub-id>
<pub-id pub-id-type="pmid">30442946</pub-id>
</element-citation>
</ref>
<ref id="B10-cancers-12-00604">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharif-Askari</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Amrein</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Aloyz</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Panasci</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines</article-title>
<source/>Breast Cancer Res. Treat.
          <year>2018</year>
<volume>172</volume>
<fpage>23</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="doi">10.1007/s10549-018-4888-6</pub-id>
<pub-id pub-id-type="pmid">30039287</pub-id>
</element-citation>
</ref>
<ref id="B11-cancers-12-00604">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oplustil O’Connor</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rulten</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Cranston</surname>
<given-names>A.N.</given-names>
</name>
<name>
<surname>Odedra</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Jaspers</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Knights</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Evers</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ting</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The PARP inhibitor AZD2461 provides insights into the role of PARP3 inhibition for both synthetic lethality and tolerability with chemotherapy in preclinical models</article-title>
<source/>Cancer Res.
          <year>2016</year>
<volume>76</volume>
<fpage>6084</fpage>
<lpage>6094</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-3240</pub-id>
<pub-id pub-id-type="pmid">27550455</pub-id>
</element-citation>
</ref>
<ref id="B12-cancers-12-00604">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Munnur</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bartlett</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mikolcevic</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kirby</surname>
<given-names>I.T.</given-names>
</name>
<name>
<surname>Matthias Rack</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Mikoc</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Ahel</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Reversible ADP-ribosylation of RNA</article-title>
<source/>Nucleic Acids Res.
          <year>2019</year>
<volume>47</volume>
<fpage>5658</fpage>
<lpage>5669</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkz305</pub-id>
<pub-id pub-id-type="pmid">31216043</pub-id>
</element-citation>
</ref>
<ref id="B13-cancers-12-00604">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schreek</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cerni</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Schamberger</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lesniewicz</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Poreba</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Vervoorts</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Walsemann</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Grotzinger</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kremmer</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PARP-10, a novel Myc-interacting protein with poly(ADP-ribose) polymerase activity, inhibits transformation</article-title>
<source/>Oncogene
          <year>2005</year>
<volume>24</volume>
<fpage>1982</fpage>
<lpage>1993</lpage>
<pub-id pub-id-type="doi">10.1038/sj.onc.1208410</pub-id>
<pub-id pub-id-type="pmid">15674325</pub-id>
</element-citation>
</ref>
<ref id="B14-cancers-12-00604">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butepage</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Preisinger</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>von Kriegsheim</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Scheufen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lausberg</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kappes</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Feederle</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ernst</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Eckei</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Nucleolar-Nucleoplasmic shuttling of TARG1 and its control by DNA damage-induced poly-ADP-ribosylation and by nucleolar transcription</article-title>
<source/>Sci. Rep.
          <year>2018</year>
<volume>8</volume>
<fpage>6748</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-018-25137-w</pub-id>
<pub-id pub-id-type="pmid">29712969</pub-id>
</element-citation>
</ref>
<ref id="B15-cancers-12-00604">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shahrour</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Nicolae</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Edvardson</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ashhab</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Galvan</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Constantin</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Abu-Libdeh</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Moldovan</surname>
<given-names>G.L.</given-names>
</name>
<name>
<surname>Elpeleg</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>PARP10 deficiency manifests by severe developmental delay and DNA repair defect</article-title>
<source/>Neurogenetics
          <year>2016</year>
<volume>17</volume>
<fpage>227</fpage>
<lpage>232</lpage>
<pub-id pub-id-type="doi">10.1007/s10048-016-0493-1</pub-id>
<pub-id pub-id-type="pmid">27624574</pub-id>
</element-citation>
</ref>
<ref id="B16-cancers-12-00604">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herzog</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hartkamp</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Verheugd</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Treude</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Forst</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Feijs</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Lippok</surname>
<given-names>B.E.</given-names>
</name>
<name>
<surname>Kremmer</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kleine</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Luscher</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Caspase-Dependent cleavage of the mono-ADP-ribosyltransferase ARTD10 interferes with its pro-apoptotic function</article-title>
<source/>FEBS J.
          <year>2013</year>
<volume>280</volume>
<fpage>1330</fpage>
<lpage>1343</lpage>
<pub-id pub-id-type="doi">10.1111/febs.12124</pub-id>
<pub-id pub-id-type="pmid">23305266</pub-id>
</element-citation>
</ref>
<ref id="B17-cancers-12-00604">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schleicher</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Galvan</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Imamura-Kawasawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Moldovan</surname>
<given-names>G.L.</given-names>
</name>
<name>
<surname>Nicolae</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>PARP10 promotes cellular proliferation and tumorigenesis by alleviating replication stress</article-title>
<source/>Nucleic Acids Res.
          <year>2018</year>
<volume>46</volume>
<fpage>8908</fpage>
<lpage>8916</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gky658</pub-id>
<pub-id pub-id-type="pmid">30032250</pub-id>
</element-citation>
</ref>
<ref id="B18-cancers-12-00604">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nicolae</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Aho</surname>
<given-names>E.R.</given-names>
</name>
<name>
<surname>Vlahos</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Choe</surname>
<given-names>K.N.</given-names>
</name>
<name>
<surname>De</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Karras</surname>
<given-names>G.I.</given-names>
</name>
<name>
<surname>Moldovan</surname>
<given-names>G.L.</given-names>
</name>
</person-group>
<article-title>The ADP-ribosyltransferase PARP10/ARTD10 interacts with proliferating cell nuclear antigen (PCNA) and is required for DNA damage tolerance</article-title>
<source/>J. Biol. Chem.
          <year>2014</year>
<volume>289</volume>
<fpage>13627</fpage>
<lpage>13637</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M114.556340</pub-id>
<pub-id pub-id-type="pmid">24695737</pub-id>
</element-citation>
</ref>
<ref id="B19-cancers-12-00604">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marton</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fodor</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nagy</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Vida</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kis</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Brunyanszki</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Antal</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Luscher</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>PARP10 (ARTD10) modulates mitochondrial function</article-title>
<source/>PLoS ONE
          <year>2018</year>
<volume>13</volume>
<elocation-id>e0187789</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0187789</pub-id>
<pub-id pub-id-type="pmid">29293500</pub-id>
</element-citation>
</ref>
<ref id="B20-cancers-12-00604">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feijs</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Kleine</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Braczynski</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Forst</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Herzog</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Verheugd</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Linzen</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Kremmer</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Luscher</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>ARTD10 substrate identification on protein microarrays: Regulation of GSK3beta by mono-ADP-ribosylation</article-title>
<source/>Cell Commun. Signal.
          <year>2013</year>
<volume>11</volume>
<fpage>5</fpage>
<pub-id pub-id-type="doi">10.1186/1478-811X-11-5</pub-id>
<pub-id pub-id-type="pmid">23332125</pub-id>
</element-citation>
</ref>
<ref id="B21-cancers-12-00604">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Troiani</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lupi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Perego</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Depaolini</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Thieffine</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bosotti</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Rusconi</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Identification of candidate substrates for poly(ADP-ribose) polymerase-2 (PARP2) in the absence of DNA damage using high-density protein microarrays</article-title>
<source/>FEBS J.
          <year>2011</year>
<volume>278</volume>
<fpage>3676</fpage>
<lpage>3687</lpage>
<pub-id pub-id-type="doi">10.1111/j.1742-4658.2011.08286.x</pub-id>
<pub-id pub-id-type="pmid">21812934</pub-id>
</element-citation>
</ref>
<ref id="B22-cancers-12-00604">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verheugd</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Forst</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Milke</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Herzog</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Feijs</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Kremmer</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kleine</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Luscher</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Regulation of NF-kappaB signalling by the mono-ADP-ribosyltransferase ARTD10</article-title>
<source/>Nat. Commun.
          <year>2013</year>
<volume>4</volume>
<fpage>1683</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms2672</pub-id>
<pub-id pub-id-type="pmid">23575687</pub-id>
</element-citation>
</ref>
<ref id="B23-cancers-12-00604">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schweiker</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Tauber</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Sherry</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Levonis</surname>
<given-names>S.M.</given-names>
</name>
</person-group>
<article-title>Structure, function and inhibition of poly(ADP-ribose)polymerase, member 14 (PARP14)</article-title>
<source/>Mini Rev. Med. Chem.
          <year>2018</year>
<volume>18</volume>
<fpage>1659</fpage>
<lpage>1669</lpage>
<pub-id pub-id-type="doi">10.2174/1389557518666180816111749</pub-id>
<pub-id pub-id-type="pmid">30112992</pub-id>
</element-citation>
</ref>
<ref id="B24-cancers-12-00604">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qin</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>L.Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>C.X.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Xing</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>P.Q.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>H.L.</given-names>
</name>
</person-group>
<article-title>Research progress on PARP14 as a drug target</article-title>
<source/>Front. Pharmacol.
          <year>2019</year>
<volume>10</volume>
<fpage>172</fpage>
<pub-id pub-id-type="doi">10.3389/fphar.2019.00172</pub-id>
<pub-id pub-id-type="pmid">30890936</pub-id>
</element-citation>
</ref>
<ref id="B25-cancers-12-00604">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jwa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>PARP16 is a tail-anchored endoplasmic reticulum protein required for the PERK-and IRE1α-mediated unfolded protein response</article-title>
<source/>Nat. Cell Biol.
          <year>2012</year>
<volume>14</volume>
<fpage>1223</fpage>
<lpage>1230</lpage>
<pub-id pub-id-type="doi">10.1038/ncb2593</pub-id>
<pub-id pub-id-type="pmid">23103912</pub-id>
</element-citation>
</ref>
<ref id="B26-cancers-12-00604">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Paola</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Micaroni</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Di Tullio</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Buccione</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Di Girolamo</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>PARP16/ARTD15 is a novel endoplasmic-reticulum-associated mono-ADP-ribosyltransferase that interacts with, and modifies karyopherin-ss1</article-title>
<source/>PLoS ONE
          <year>2012</year>
<volume>7</volume>
<elocation-id>e37352</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0037352</pub-id>
<pub-id pub-id-type="pmid">22701565</pub-id>
</element-citation>
</ref>
<ref id="B27-cancers-12-00604">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Atasheva</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Frolova</surname>
<given-names>E.I.</given-names>
</name>
<name>
<surname>Frolov</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Interferon-Stimulated poly(ADP-Ribose) polymerases are potent inhibitors of cellular translation and virus replication</article-title>
<source/>J. Virol.
          <year>2014</year>
<volume>88</volume>
<fpage>2116</fpage>
<lpage>2130</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.03443-13</pub-id>
<pub-id pub-id-type="pmid">24335297</pub-id>
</element-citation>
</ref>
<ref id="B28-cancers-12-00604">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Atasheva</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Akhrymuk</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Frolova</surname>
<given-names>E.I.</given-names>
</name>
<name>
<surname>Frolov</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>New PARP gene with an anti-alphavirus function</article-title>
<source/>J. Virol.
          <year>2012</year>
<volume>86</volume>
<fpage>8147</fpage>
<lpage>8160</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.00733-12</pub-id>
<pub-id pub-id-type="pmid">22623789</pub-id>
</element-citation>
</ref>
<ref id="B29-cancers-12-00604">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Imai</surname>
<given-names>S.I.</given-names>
</name>
<name>
<surname>Guarente</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>It takes two to tango: NAD+ and sirtuins in aging/longevity control</article-title>
<source/>NPJ Aging Mech. Dis.
          <year>2016</year>
<volume>2</volume>
<fpage>16017</fpage>
<pub-id pub-id-type="doi">10.1038/npjamd.2016.17</pub-id>
<pub-id pub-id-type="pmid">28721271</pub-id>
</element-citation>
</ref>
<ref id="B30-cancers-12-00604">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feldman</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Dittenhafer-Reed</surname>
<given-names>K.E.</given-names>
</name>
<name>
<surname>Denu</surname>
<given-names>J.M.</given-names>
</name>
</person-group>
<article-title>Sirtuin catalysis and regulation</article-title>
<source/>J. Biol. Chem.
          <year>2012</year>
<volume>287</volume>
<fpage>42419</fpage>
<lpage>42427</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.R112.378877</pub-id>
<pub-id pub-id-type="pmid">23086947</pub-id>
</element-citation>
</ref>
<ref id="B31-cancers-12-00604">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Du</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Investigating the ADP-ribosyltransferase activity of sirtuins with NAD analogues and 32P-NAD</article-title>
<source/>Biochemistry
          <year>2009</year>
<volume>48</volume>
<fpage>2878</fpage>
<lpage>2890</lpage>
<pub-id pub-id-type="doi">10.1021/bi802093g</pub-id>
<pub-id pub-id-type="pmid">19220062</pub-id>
</element-citation>
</ref>
<ref id="B32-cancers-12-00604">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haigis</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Mostoslavsky</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Haigis</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Fahie</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Christodoulou</surname>
<given-names>D.C.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Valenzuela</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Yancopoulos</surname>
<given-names>G.D.</given-names>
</name>
<name>
<surname>Karow</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Blander</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells</article-title>
<source/>Cell
          <year>2006</year>
<volume>126</volume>
<fpage>941</fpage>
<lpage>954</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2006.06.057</pub-id>
<pub-id pub-id-type="pmid">16959573</pub-id>
</element-citation>
</ref>
<ref id="B33-cancers-12-00604">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hine</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Van Meter</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Au</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vaidya</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Seluanov</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gorbunova</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>SIRT6 promotes DNA repair under stress by activating PARP1</article-title>
<source/>Science
          <year>2011</year>
<volume>332</volume>
<fpage>1443</fpage>
<lpage>1446</lpage>
<pub-id pub-id-type="doi">10.1126/science.1202723</pub-id>
<pub-id pub-id-type="pmid">21680843</pub-id>
</element-citation>
</ref>
<ref id="B34-cancers-12-00604">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rezazadeh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tombline</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Regan</surname>
<given-names>S.P.</given-names>
</name>
<name>
<surname>Seluanov</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gorbunova</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>SIRT6 promotes transcription of a subset of NRF2 targets by mono-ADP-ribosylating BAF170</article-title>
<source/>Nucleic Acids Res.
          <year>2019</year>
<volume>47</volume>
<fpage>7914</fpage>
<lpage>7928</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkz528</pub-id>
<pub-id pub-id-type="pmid">31216030</pub-id>
</element-citation>
</ref>
<ref id="B35-cancers-12-00604">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitra</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Dey</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Biochemical characterization of mono ADP ribosyl transferase activity of human sirtuin SIRT7 and its regulation</article-title>
<source/>Arch. Biochem. Biophys.
          <year>2019</year>
<volume>680</volume>
<fpage>108226</fpage>
<pub-id pub-id-type="doi">10.1016/j.abb.2019.108226</pub-id>
<pub-id pub-id-type="pmid">31843644</pub-id>
</element-citation>
</ref>
<ref id="B36-cancers-12-00604">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luscher</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Butepage</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Eckei</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Krieg</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Verheugd</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Shilton</surname>
<given-names>B.H.</given-names>
</name>
</person-group>
<article-title>ADP-Ribosylation, a multifaceted posttranslational modification involved in the control of cell physiology in health and disease</article-title>
<source/>Chem. Rev.
          <year>2018</year>
<volume>118</volume>
<fpage>1092</fpage>
<lpage>1136</lpage>
<pub-id pub-id-type="doi">10.1021/acs.chemrev.7b00122</pub-id>
<pub-id pub-id-type="pmid">29172462</pub-id>
</element-citation>
</ref>
<ref id="B37-cancers-12-00604">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pehrson</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Fried</surname>
<given-names>V.A.</given-names>
</name>
</person-group>
<article-title>MacroH2A, a core histone containing a large nonhistone region</article-title>
<source/>Science
          <year>1992</year>
<volume>257</volume>
<fpage>1398</fpage>
<lpage>1400</lpage>
<pub-id pub-id-type="doi">10.1126/science.1529340</pub-id>
<pub-id pub-id-type="pmid">1529340</pub-id>
</element-citation>
</ref>
<ref id="B38-cancers-12-00604">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Timinszky</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Till</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hassa</surname>
<given-names>P.O.</given-names>
</name>
<name>
<surname>Hothorn</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kustatscher</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Nijmeijer</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Colombelli</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Altmeyer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Stelzer</surname>
<given-names>E.H.</given-names>
</name>
<name>
<surname>Scheffzek</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A macrodomain-containing histone rearranges chromatin upon sensing PARP1 activation</article-title>
<source/>Nat. Struct. Mol. Biol.
          <year>2009</year>
<volume>16</volume>
<fpage>923</fpage>
<lpage>929</lpage>
<pub-id pub-id-type="doi">10.1038/nsmb.1664</pub-id>
<pub-id pub-id-type="pmid">19680243</pub-id>
</element-citation>
</ref>
<ref id="B39-cancers-12-00604">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rack</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Perina</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ahel</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Macrodomains: Structure, function, evolution, and catalytic activities</article-title>
<source/>Annu. Rev. Biochem.
          <year>2016</year>
<volume>85</volume>
<fpage>431</fpage>
<lpage>454</lpage>
<pub-id pub-id-type="doi">10.1146/annurev-biochem-060815-014935</pub-id>
<pub-id pub-id-type="pmid">26844395</pub-id>
</element-citation>
</ref>
<ref id="B40-cancers-12-00604">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neuvonen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ahola</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Differential activities of cellular and viral macro domain proteins in binding of ADP-ribose metabolites</article-title>
<source/>J. Mol. Biol.
          <year>2009</year>
<volume>385</volume>
<fpage>212</fpage>
<lpage>225</lpage>
<pub-id pub-id-type="doi">10.1016/j.jmb.2008.10.045</pub-id>
<pub-id pub-id-type="pmid">18983849</pub-id>
</element-citation>
</ref>
<ref id="B41-cancers-12-00604">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karras</surname>
<given-names>G.I.</given-names>
</name>
<name>
<surname>Kustatscher</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Buhecha</surname>
<given-names>H.R.</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Pugieux</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sait</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bycroft</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ladurner</surname>
<given-names>A.G.</given-names>
</name>
</person-group>
<article-title>The macro domain is an ADP-ribose binding module</article-title>
<source/>EMBO J.
          <year>2005</year>
<volume>24</volume>
<fpage>1911</fpage>
<lpage>1920</lpage>
<pub-id pub-id-type="doi">10.1038/sj.emboj.7600664</pub-id>
<pub-id pub-id-type="pmid">15902274</pub-id>
</element-citation>
</ref>
<ref id="B42-cancers-12-00604">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kustatscher</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hothorn</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pugieux</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Scheffzek</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ladurner</surname>
<given-names>A.G.</given-names>
</name>
</person-group>
<article-title>Splicing regulates NAD metabolite binding to histone macroH2A</article-title>
<source/>Nat. Struct. Mol. Biol.
          <year>2005</year>
<volume>12</volume>
<fpage>624</fpage>
<lpage>625</lpage>
<pub-id pub-id-type="doi">10.1038/nsmb956</pub-id>
<pub-id pub-id-type="pmid">15965484</pub-id>
</element-citation>
</ref>
<ref id="B43-cancers-12-00604">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feijs</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Forst</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Verheugd</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Luscher</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Macrodomain-Containing proteins: Regulating new intracellular functions of mono(ADP-ribosyl)ation</article-title>
<source/>Nat. Rev. Mol. Cell Biol.
          <year>2013</year>
<volume>14</volume>
<fpage>443</fpage>
<lpage>451</lpage>
<pub-id pub-id-type="doi">10.1038/nrm3601</pub-id>
<pub-id pub-id-type="pmid">23736681</pub-id>
</element-citation>
</ref>
<ref id="B44-cancers-12-00604">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Slade</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Dunstan</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Barkauskaite</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Weston</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lafite</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Dixon</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ahel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Leys</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ahel</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>The structure and catalytic mechanism of a poly(ADP-ribose) glycohydrolase</article-title>
<source/>Nature
          <year>2011</year>
<volume>477</volume>
<fpage>616</fpage>
<lpage>620</lpage>
<pub-id pub-id-type="doi">10.1038/nature10404</pub-id>
<pub-id pub-id-type="pmid">21892188</pub-id>
</element-citation>
</ref>
<ref id="B45-cancers-12-00604">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharifi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Morra</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Appel</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>Tallis</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chioza</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Jankevicius</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Simpson</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Matic</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ozkan</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Golia</surname>
<given-names>B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Deficiency of terminal ADP-ribose protein glycohydrolase TARG1/C6orf130 in neurodegenerative disease</article-title>
<source/>EMBO J.
          <year>2013</year>
<volume>32</volume>
<fpage>1225</fpage>
<lpage>1237</lpage>
<pub-id pub-id-type="doi">10.1038/emboj.2013.51</pub-id>
<pub-id pub-id-type="pmid">23481255</pub-id>
</element-citation>
</ref>
<ref id="B46-cancers-12-00604">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jankevicius</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hassler</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Golia</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Rybin</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Zacharias</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Timinszky</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ladurner</surname>
<given-names>A.G.</given-names>
</name>
</person-group>
<article-title>A family of macrodomain proteins reverses cellular mono-ADP-ribosylation</article-title>
<source/>Nat. Struct. Mol. Biol.
          <year>2013</year>
<volume>20</volume>
<fpage>508</fpage>
<lpage>514</lpage>
<pub-id pub-id-type="doi">10.1038/nsmb.2523</pub-id>
<pub-id pub-id-type="pmid">23474712</pub-id>
</element-citation>
</ref>
<ref id="B47-cancers-12-00604">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosenthal</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Feijs</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Frugier</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Bonalli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Forst</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Imhof</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Winkler</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Caflisch</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hassa</surname>
<given-names>P.O.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Macrodomain-Containing proteins are new mono-ADP-ribosylhydrolases</article-title>
<source/>Nat. Struct. Mol. Biol.
          <year>2013</year>
<volume>20</volume>
<fpage>502</fpage>
<lpage>507</lpage>
<pub-id pub-id-type="doi">10.1038/nsmb.2521</pub-id>
<pub-id pub-id-type="pmid">23474714</pub-id>
</element-citation>
</ref>
<ref id="B48-cancers-12-00604">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dudkiewicz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pawlowski</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>A novel conserved family of macro-like domains-putative new players in ADP-ribosylation signaling</article-title>
<source/>PeerJ
          <year>2019</year>
<volume>7</volume>
<fpage>e6863</fpage>
<pub-id pub-id-type="doi">10.7717/peerj.6863</pub-id>
<pub-id pub-id-type="pmid">31106069</pub-id>
</element-citation>
</ref>
<ref id="B49-cancers-12-00604">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Egloff</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Malet</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Putics</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Heinonen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dutartre</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Frangeul</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gruez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Campanacci</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Cambillau</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ziebuhr</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Structural and functional basis for ADP-ribose and poly(ADP-ribose) binding by viral macro domains</article-title>
<source/>J. Virol.
          <year>2006</year>
<volume>80</volume>
<fpage>8493</fpage>
<lpage>8502</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.00713-06</pub-id>
<pub-id pub-id-type="pmid">16912299</pub-id>
</element-citation>
</ref>
<ref id="B50-cancers-12-00604">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eckei</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Krieg</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Butepage</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lehmann</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gross</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lippok</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Grimm</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Kummerer</surname>
<given-names>B.M.</given-names>
</name>
<name>
<surname>Rossetti</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Luscher</surname>
<given-names>B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The conserved macrodomains of the non-structural proteins of Chikungunya virus and other pathogenic positive strand RNA viruses function as mono-ADP-ribosylhydrolases</article-title>
<source/>Sci. Rep.
          <year>2017</year>
<volume>7</volume>
<fpage>41746</fpage>
<pub-id pub-id-type="doi">10.1038/srep41746</pub-id>
<pub-id pub-id-type="pmid">28150709</pub-id>
</element-citation>
</ref>
<ref id="B51-cancers-12-00604">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fehr</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Channappanavar</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Jankevicius</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Fett</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Athmer</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Meyerholz</surname>
<given-names>D.K.</given-names>
</name>
<name>
<surname>Ahel</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Perlman</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>The conserved Coronavirus macrodomain promotes virulence and suppresses the innate immune response during severe acute respiratory syndrome Coronavirus infection</article-title>
<source/>mBio
          <year>2016</year>
<fpage>7</fpage>
<pub-id pub-id-type="doi">10.1128/mBio.01721-16</pub-id>
<pub-id pub-id-type="pmid">27965448</pub-id>
</element-citation>
</ref>
<ref id="B52-cancers-12-00604">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Debing</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jankevicius</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Neyts</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ahel</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Coutard</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Canard</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Viral macro domains reverse protein ADP-ribosylation</article-title>
<source/>J. Virol.
          <year>2016</year>
<volume>90</volume>
<fpage>8478</fpage>
<lpage>8486</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.00705-16</pub-id>
<pub-id pub-id-type="pmid">27440879</pub-id>
</element-citation>
</ref>
<ref id="B53-cancers-12-00604">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daugherty</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Kerns</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Malik</surname>
<given-names>H.S.</given-names>
</name>
</person-group>
<article-title>Rapid evolution of PARP genes suggests a broad role for ADP-ribosylation in host-virus conflicts</article-title>
<source/>PLoS Genet.
          <year>2014</year>
<volume>10</volume>
<elocation-id>e1004403</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1004403</pub-id>
<pub-id pub-id-type="pmid">24875882</pub-id>
</element-citation>
</ref>
<ref id="B54-cancers-12-00604">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tanuma</surname>
<given-names>S.I.</given-names>
</name>
<name>
<surname>Shibui</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Oyama</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Uchiumi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Abe</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Targeting poly(ADP-ribose) glycohydrolase to draw apoptosis codes in cancer</article-title>
<source/>Biochem. Pharm.
          <year>2019</year>
<volume>167</volume>
<fpage>163</fpage>
<lpage>172</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcp.2019.06.004</pub-id>
<pub-id pub-id-type="pmid">31176615</pub-id>
</element-citation>
</ref>
<ref id="B55-cancers-12-00604">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>N.F.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fung</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Isolation and characterization of a novel oncogene, amplified in liver cancer 1, within a commonly amplified region at 1q21 in hepatocellular carcinoma</article-title>
<source/>Hepatology
          <year>2008</year>
<volume>47</volume>
<fpage>503</fpage>
<lpage>510</lpage>
<pub-id pub-id-type="doi">10.1002/hep.22072</pub-id>
<pub-id pub-id-type="pmid">18023026</pub-id>
</element-citation>
</ref>
<ref id="B56-cancers-12-00604">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peterson</surname>
<given-names>F.C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lytle</surname>
<given-names>B.L.</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>M.N.</given-names>
</name>
<name>
<surname>Ahel</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Denu</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Volkman</surname>
<given-names>B.F.</given-names>
</name>
</person-group>
<article-title>Orphan macrodomain protein (human C6orf130) is an O-acyl-ADP-ribose deacylase: Solution structure and catalytic properties</article-title>
<source/>J. Biol. Chem.
          <year>2011</year>
<volume>286</volume>
<fpage>35955</fpage>
<lpage>35965</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M111.276238</pub-id>
<pub-id pub-id-type="pmid">21849506</pub-id>
</element-citation>
</ref>
<ref id="B57-cancers-12-00604">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Vollmar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>M.N.</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kraehenbuehl</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Slade</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mehrotra</surname>
<given-names>P.V.</given-names>
</name>
<name>
<surname>von Delft</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Crosthwaite</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Gileadi</surname>
<given-names>O.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of macrodomain proteins as novel O-acetyl-ADP-ribose deacetylases</article-title>
<source/>J. Biol. Chem.
          <year>2011</year>
<volume>286</volume>
<fpage>13261</fpage>
<lpage>13271</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M110.206771</pub-id>
<pub-id pub-id-type="pmid">21257746</pub-id>
</element-citation>
</ref>
<ref id="B58-cancers-12-00604">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tong</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Denu</surname>
<given-names>J.M.</given-names>
</name>
</person-group>
<article-title>Function and metabolism of sirtuin metabolite O-acetyl-ADP-ribose</article-title>
<source/>Biochim. Biophys. Acta
          <year>2010</year>
<volume>1804</volume>
<fpage>1617</fpage>
<lpage>1625</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbapap.2010.02.007</pub-id>
<pub-id pub-id-type="pmid">20176146</pub-id>
</element-citation>
</ref>
<ref id="B59-cancers-12-00604">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Structure-Function analyses reveal the mechanism of the ARH3-dependent hydrolysis of ADP-ribosylation</article-title>
<source/>J. Biol. Chem.
          <year>2018</year>
<volume>293</volume>
<fpage>14470</fpage>
<lpage>14480</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.RA118.004284</pub-id>
<pub-id pub-id-type="pmid">30045870</pub-id>
</element-citation>
</ref>
<ref id="B60-cancers-12-00604">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abplanalp</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Leutert</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Frugier</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Nowak</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Feurer</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kistemaker</surname>
<given-names>H.V.A.</given-names>
</name>
<name>
<surname>Filippov</surname>
<given-names>D.V.</given-names>
</name>
<name>
<surname>Moss</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Caflisch</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Proteomic analyses identify ARH3 as a serine mono-ADP-ribosylhydrolase</article-title>
<source/>Nat. Commun.
          <year>2017</year>
<volume>8</volume>
<fpage>2055</fpage>
<pub-id pub-id-type="doi">10.1038/s41467-017-02253-1</pub-id>
<pub-id pub-id-type="pmid">29234005</pub-id>
</element-citation>
</ref>
<ref id="B61-cancers-12-00604">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fontana</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bonfiglio</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Palazzo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bartlett</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Matic</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ahel</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Serine ADP-ribosylation reversal by the hydrolase ARH3</article-title>
<source/>eLife
          <year>2017</year>
<volume>6</volume>
<pub-id pub-id-type="doi">10.7554/eLife.28533</pub-id>
<pub-id pub-id-type="pmid">28650317</pub-id>
</element-citation>
</ref>
<ref id="B62-cancers-12-00604">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moss</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Stanley</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Nightingale</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Murtagh</surname>
<given-names>J.J.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Monaco</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mishima</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Williamson</surname>
<given-names>K.C.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>S.C.</given-names>
</name>
</person-group>
<article-title>Molecular and immunological characterization of ADP-ribosylarginine hydrolases</article-title>
<source/>J. Biol. Chem.
          <year>1992</year>
<volume>267</volume>
<fpage>10481</fpage>
<lpage>10488</lpage>
<pub-id pub-id-type="pmid">1375222</pub-id>
</element-citation>
</ref>
<ref id="B63-cancers-12-00604">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Munnur</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ahel</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Reversible mono-ADP-ribosylation of DNA breaks</article-title>
<source/>FEBS J.
          <year>2017</year>
<volume>284</volume>
<fpage>4002</fpage>
<lpage>4016</lpage>
<pub-id pub-id-type="doi">10.1111/febs.14297</pub-id>
<pub-id pub-id-type="pmid">29054115</pub-id>
</element-citation>
</ref>
<ref id="B64-cancers-12-00604">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stevens</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kasamatsu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Oda</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>D.Y.</given-names>
</name>
<name>
<surname>Moss</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>The ARH and macrodomain families of α-ADP-ribose-acceptor hydrolases catalyze α-NAD<sup>+</sup> hydrolysis</article-title>
<source/>ACS Chem. Biol.
          <year>2019</year>
<volume>14</volume>
<fpage>2576</fpage>
<lpage>2584</lpage>
<pub-id pub-id-type="doi">10.1021/acschembio.9b00429</pub-id>
<pub-id pub-id-type="pmid">31599159</pub-id>
</element-citation>
</ref>
<ref id="B65-cancers-12-00604">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gibson</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Conrad</surname>
<given-names>L.B.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kraus</surname>
<given-names>W.L.</given-names>
</name>
</person-group>
<article-title>Generation and characterization of recombinant antibody-like ADP-ribose binding proteins</article-title>
<source/>Biochemistry
          <year>2017</year>
<volume>56</volume>
<fpage>6305</fpage>
<lpage>6316</lpage>
<pub-id pub-id-type="doi">10.1021/acs.biochem.7b00670</pub-id>
<pub-id pub-id-type="pmid">29053245</pub-id>
</element-citation>
</ref>
<ref id="B66-cancers-12-00604">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>A.Z.</given-names>
</name>
<name>
<surname>Abo</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gui</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Mo</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Blackwell</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wigle</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Keilhack</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Niepel</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Enabling drug discovery for the PARP protein family through the detection of mono-ADP-ribosylation</article-title>
<source/>Biochem. Pharmacol.
          <year>2019</year>
<volume>167</volume>
<fpage>97</fpage>
<lpage>106</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcp.2019.05.007</pub-id>
<pub-id pub-id-type="pmid">31075269</pub-id>
</element-citation>
</ref>
<ref id="B67-cancers-12-00604">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butepage</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Krieg</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Eckei</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rossetti</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Verheugd</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Luscher</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Assessment of intracellular auto-modification levels of ARTD10 using mono-ADP-ribose-specific macrodomains 2 and 3 of murine Artd8</article-title>
<source/>Methods Mol. Biol.
          <year>2018</year>
<volume>1813</volume>
<fpage>41</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="doi">10.1007/978-1-4939-8588-3_4</pub-id>
<pub-id pub-id-type="pmid">30097860</pub-id>
</element-citation>
</ref>
<ref id="B68-cancers-12-00604">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haikarainen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Maksimainen</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Obaji</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Lehtio</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Development of an inhibitor screening assay for mono-ADP-ribosyl hydrolyzing macrodomains using AlphaScreen technology</article-title>
<source/>SLAS Discov.
          <year>2018</year>
<volume>23</volume>
<fpage>255</fpage>
<lpage>263</lpage>
<pub-id pub-id-type="doi">10.1177/2472555217737006</pub-id>
<pub-id pub-id-type="pmid">29028410</pub-id>
</element-citation>
</ref>
<ref id="B69-cancers-12-00604">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moustakim</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Riedel</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Schuller</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gehring</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Monteiro</surname>
<given-names>O.P.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>S.P.</given-names>
</name>
<name>
<surname>Fedorov</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Heer</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dixon</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Elkins</surname>
<given-names>J.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Discovery of a novel allosteric inhibitor scaffold for polyadenosine-diphosphate-ribose polymerase 14 (PARP14) macrodomain 2</article-title>
<source/>Bioorg. Med. Chem.
          <year>2018</year>
<volume>26</volume>
<fpage>2965</fpage>
<lpage>2972</lpage>
<pub-id pub-id-type="doi">10.1016/j.bmc.2018.03.020</pub-id>
<pub-id pub-id-type="pmid">29567296</pub-id>
</element-citation>
</ref>
<ref id="B70-cancers-12-00604">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Žaja</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Aydin</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Lippok</surname>
<given-names>B.E.</given-names>
</name>
<name>
<surname>Lüscher</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Feijs</surname>
<given-names>K.L.</given-names>
</name>
</person-group>
<article-title>A comparative analysis of MacroD1, MACROD2 and TARG1 expression, localisation and interactome</article-title>
<source/>Sci. Rep
          <comment>under review</comment>
</element-citation>
</ref>
<ref id="B71-cancers-12-00604">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agnew</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Munnur</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Palazzo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mikoc</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ahel</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>MacroD1 is a promiscuous ADP-ribosyl hydrolase localized to mitochondria</article-title>
<source/>Front. Microbiol.
          <year>2018</year>
<volume>9</volume>
<fpage>20</fpage>
<pub-id pub-id-type="doi">10.3389/fmicb.2018.00020</pub-id>
<pub-id pub-id-type="pmid">29410655</pub-id>
</element-citation>
</ref>
<ref id="B72-cancers-12-00604">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>W.D.</given-names>
</name>
<name>
<surname>Si</surname>
<given-names>Y.L.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z.Q.</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>H.J.</given-names>
</name>
</person-group>
<article-title>GC-Rich promoter elements maximally confers estrogen-induced transactivation of LRP16 gene through ERalpha/Sp1 interaction in MCF-7 cells</article-title>
<source/>J. Steroid Biochem. Mol. Biol.
          <year>2008</year>
<volume>109</volume>
<fpage>47</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="doi">10.1016/j.jsbmb.2007.12.009</pub-id>
<pub-id pub-id-type="pmid">18206366</pub-id>
</element-citation>
</ref>
<ref id="B73-cancers-12-00604">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>Y.L.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>W.D.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Mu</surname>
<given-names>Y.M.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>X.C.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>C.Y.</given-names>
</name>
</person-group>
<article-title>Mechanism of transcriptional regulation of LRP16 gene expression by 17-beta estradiol in MCF-7 human breast cancer cells</article-title>
<source/>J. Mol. Endocrinol.
          <year>2005</year>
<volume>34</volume>
<fpage>77</fpage>
<lpage>89</lpage>
<pub-id pub-id-type="doi">10.1677/jme.1.01628</pub-id>
<pub-id pub-id-type="pmid">15691879</pub-id>
</element-citation>
</ref>
<ref id="B74-cancers-12-00604">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>W.D.</given-names>
</name>
<name>
<surname>Mu</surname>
<given-names>Y.M.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>X.C.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Z.M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.J.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Up-Regulation of LRP16 mRNA by 17beta-estradiol through activation of estrogen receptor alpha (ERalpha), but not ERbeta, and promotion of human breast cancer MCF-7 cell proliferation: A preliminary report</article-title>
<source/>Endocr. Relat. Cancer
          <year>2003</year>
<volume>10</volume>
<fpage>217</fpage>
<lpage>224</lpage>
<pub-id pub-id-type="doi">10.1677/erc.0.0100217</pub-id>
<pub-id pub-id-type="pmid">12790785</pub-id>
</element-citation>
</ref>
<ref id="B75-cancers-12-00604">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Golia</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Moeller</surname>
<given-names>G.K.</given-names>
</name>
<name>
<surname>Jankevicius</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hegele</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Preisser</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tran</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Imhof</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Timinszky</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>ATM induces MACROD2 nuclear export upon DNA damage</article-title>
<source/>Nucleic Acids Res.
          <year>2017</year>
<volume>45</volume>
<fpage>244</fpage>
<lpage>254</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkw904</pub-id>
<pub-id pub-id-type="pmid">28069995</pub-id>
</element-citation>
</ref>
<ref id="B76-cancers-12-00604">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ito</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Morishita</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mizuno</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kawamura</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tabata</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nagata</surname>
<given-names>K.I.</given-names>
</name>
</person-group>
<article-title>Biochemical and morphological characterization of a neurodevelopmental disorder-related mono-ADP-ribosylhydrolase, MACRO domain containing 2</article-title>
<source/>Dev. Neurosci.
          <year>2018</year>
<volume>40</volume>
<fpage>278</fpage>
<lpage>287</lpage>
<pub-id pub-id-type="doi">10.1159/000492271</pub-id>
<pub-id pub-id-type="pmid">30227424</pub-id>
</element-citation>
</ref>
<ref id="B77-cancers-12-00604">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lombardo</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Esposito</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Iossa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vitale</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Verdesca</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Perrotta</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Di Leo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Pastore</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Franze</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Intragenic deletion in MACROD2: A family with complex phenotypes including microcephaly, intellectual disability, polydactyly, renal and pancreatic malformations</article-title>
<source/>Cytogenet. Genome Res.
          <year>2019</year>
<volume>158</volume>
<fpage>25</fpage>
<lpage>31</lpage>
<pub-id pub-id-type="doi">10.1159/000499886</pub-id>
<pub-id pub-id-type="pmid">31055587</pub-id>
</element-citation>
</ref>
<ref id="B78-cancers-12-00604">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jones</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Cadby</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Blangero</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Abraham</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Whitehouse</surname>
<given-names>A.J.O.</given-names>
</name>
<name>
<surname>Moses</surname>
<given-names>E.K.</given-names>
</name>
</person-group>
<article-title>MACROD2 gene associated with autistic-like traits in a general population sample</article-title>
<source/>Psychiatr. Genet.
          <year>2014</year>
<volume>24</volume>
<fpage>241</fpage>
<lpage>248</lpage>
<pub-id pub-id-type="doi">10.1097/YPG.0000000000000052</pub-id>
<pub-id pub-id-type="pmid">25360606</pub-id>
</element-citation>
</ref>
<ref id="B79-cancers-12-00604">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Curran</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bolton</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Rozsnyai</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Chiocchetti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Klauck</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Duketis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Poustka</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Schlitt</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Freitag</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>I.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>No association between a common single nucleotide polymorphism, rs4141463, in the MACROD2 gene and autism spectrum disorder</article-title>
<source/>Am. J. Med. Genet. B Neuropsychiatr. Genet.
          <year>2011</year>
<volume>156</volume>
<fpage>633</fpage>
<lpage>639</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.b.31201</pub-id>
</element-citation>
</ref>
<ref id="B80-cancers-12-00604">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anney</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Klei</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pinto</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Regan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Conroy</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Magalhaes</surname>
<given-names>T.R.</given-names>
</name>
<name>
<surname>Correia</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Abrahams</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Sykes</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Pagnamenta</surname>
<given-names>A.T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A genome-wide scan for common alleles affecting risk for autism</article-title>
<source/>Hum. Mol. Genet.
          <year>2010</year>
<volume>19</volume>
<fpage>4072</fpage>
<lpage>4082</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddq307</pub-id>
<pub-id pub-id-type="pmid">20663923</pub-id>
</element-citation>
</ref>
<ref id="B81-cancers-12-00604">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bilinovich</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Grepo</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>D.B.</given-names>
</name>
</person-group>
<article-title>The long noncoding RNA RPS10P2-AS1 is implicated in autism spectrum disorder risk and modulates gene expression in human neuronal progenitor cells</article-title>
<source/>Front. Genet.
          <year>2019</year>
<volume>10</volume>
<fpage>970</fpage>
<pub-id pub-id-type="doi">10.3389/fgene.2019.00970</pub-id>
<pub-id pub-id-type="pmid">31681417</pub-id>
</element-citation>
</ref>
<ref id="B82-cancers-12-00604">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>Y.C.</given-names>
</name>
<name>
<surname>Hee</surname>
<given-names>S.W.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.Y.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>M.W.</given-names>
</name>
<name>
<surname>Hung</surname>
<given-names>Y.J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>I.T.</given-names>
</name>
<name>
<surname>Hung</surname>
<given-names>K.Y.</given-names>
</name>
<name>
<surname>Assimes</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genome-Wide scan for circulating vascular adhesion protein-1 levels: MACROD2 as a potential transcriptional regulator of adipogenesis</article-title>
<source/>J. Diabetes Investig.
          <year>2018</year>
<volume>9</volume>
<fpage>1067</fpage>
<lpage>1074</lpage>
<pub-id pub-id-type="doi">10.1111/jdi.12805</pub-id>
<pub-id pub-id-type="pmid">29364582</pub-id>
</element-citation>
</ref>
<ref id="B83-cancers-12-00604">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.L.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z.Q.</given-names>
</name>
<name>
<surname>Si</surname>
<given-names>Y.L.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>Y.G.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>X.B.</given-names>
</name>
<name>
<surname>Mu</surname>
<given-names>Y.M.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>W.D.</given-names>
</name>
</person-group>
<article-title>The single-macro domain protein LRP16 is an essential cofactor of androgen receptor</article-title>
<source/>Endocr. Relat. Cancer
          <year>2009</year>
<volume>16</volume>
<fpage>139</fpage>
<lpage>153</lpage>
<pub-id pub-id-type="doi">10.1677/ERC-08-0150</pub-id>
<pub-id pub-id-type="pmid">19022849</pub-id>
</element-citation>
</ref>
<ref id="B84-cancers-12-00604">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bindesboll</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bott</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tamblyn</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>MacPherson</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gronning-Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Nebb</surname>
<given-names>H.I.</given-names>
</name>
<name>
<surname>Matthews</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>TCDD-Inducible poly-ADP-ribose polymerase (TIPARP/PARP7) mono-ADP-ribosylates and co-activates liver X receptors</article-title>
<source/>Biochem. J.
          <year>2016</year>
<volume>473</volume>
<fpage>899</fpage>
<lpage>910</lpage>
<pub-id pub-id-type="doi">10.1042/BJ20151077</pub-id>
<pub-id pub-id-type="pmid">26814197</pub-id>
</element-citation>
</ref>
<ref id="B85-cancers-12-00604">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahmed</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bott</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gomez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tamblyn</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rasheed</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>MacPherson</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sugamori</surname>
<given-names>K.S.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>D.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Loss of the mono-ADP-ribosyltransferase, Tiparp, increases sensitivity to dioxin-induced steatohepatitis and lethality</article-title>
<source/>J. Biol. Chem.
          <year>2015</year>
<volume>290</volume>
<fpage>16824</fpage>
<lpage>16840</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M115.660100</pub-id>
<pub-id pub-id-type="pmid">25975270</pub-id>
</element-citation>
</ref>
<ref id="B86-cancers-12-00604">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ti</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Si</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Mei</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>LRP16 integrates into NF-kappaB transcriptional complex and is required for its functional activation</article-title>
<source/>PLoS ONE
          <year>2011</year>
<volume>6</volume>
<elocation-id>e18157</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0018157</pub-id>
<pub-id pub-id-type="pmid">21483817</pub-id>
</element-citation>
</ref>
<ref id="B87-cancers-12-00604">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Mei</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>An LRP16-containing preassembly complex contributes to NF-kappaB activation induced by DNA double-strand breaks</article-title>
<source/>Nucleic Acids Res.
          <year>2015</year>
<volume>43</volume>
<fpage>3167</fpage>
<lpage>3179</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkv161</pub-id>
<pub-id pub-id-type="pmid">25735744</pub-id>
</element-citation>
</ref>
<ref id="B88-cancers-12-00604">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>An</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Mei</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hanski</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ahola</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Blockade of the LRP16-PKR-NF-kappaB signaling axis sensitizes colorectal carcinoma cells to DNA-damaging cytotoxic therapy</article-title>
<source/>eLife
          <year>2017</year>
<volume>6</volume>
<pub-id pub-id-type="doi">10.7554/eLife.27301</pub-id>
</element-citation>
</ref>
<ref id="B89-cancers-12-00604">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>W.D.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.L.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>Y.G.</given-names>
</name>
<name>
<surname>Zang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z.Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Si</surname>
<given-names>Y.L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ba</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Morinaga</surname>
<given-names>H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Estrogenically regulated LRP16 interacts with estrogen receptor alpha and enhances the receptor’s transcriptional activity</article-title>
<source/>Endocr. Relat. Cancer
          <year>2007</year>
<volume>14</volume>
<fpage>741</fpage>
<lpage>753</lpage>
<pub-id pub-id-type="doi">10.1677/ERC-06-0082</pub-id>
<pub-id pub-id-type="pmid">17914104</pub-id>
</element-citation>
</ref>
<ref id="B90-cancers-12-00604">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tian</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Si</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Mu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Differential induction of LRP16 by liganded and unliganded estrogen receptor alpha in SKOV3 ovarian carcinoma cells</article-title>
<source/>J. Endocrinol.
          <year>2009</year>
<volume>202</volume>
<fpage>167</fpage>
<lpage>177</lpage>
<pub-id pub-id-type="doi">10.1677/JOE-09-0054</pub-id>
<pub-id pub-id-type="pmid">19403568</pub-id>
</element-citation>
</ref>
<ref id="B91-cancers-12-00604">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roux</surname>
<given-names>K.J.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>D.I.</given-names>
</name>
<name>
<surname>Burke</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>BioID: A screen for protein-protein interactions</article-title>
<source/>Curr. Protoc. Protein Sci.
          <year>2013</year>
<volume>74</volume>
<pub-id pub-id-type="doi">10.1002/0471140864.ps1923s74</pub-id>
<pub-id pub-id-type="pmid">24510646</pub-id>
</element-citation>
</ref>
<ref id="B92-cancers-12-00604">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Curtin</surname>
<given-names>N.J.</given-names>
</name>
</person-group>
<article-title>PARP inhibitors for cancer therapy</article-title>
<source/>Expert Rev. Mol. Med.
          <year>2005</year>
<volume>7</volume>
<fpage>1</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="doi">10.1017/S146239940500904X</pub-id>
<pub-id pub-id-type="pmid">15836799</pub-id>
</element-citation>
</ref>
<ref id="B93-cancers-12-00604">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davar</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Beumer</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Hamieh</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tawbi</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Role of PARP inhibitors in cancer biology and therapy</article-title>
<source/>Curr. Med. Chem.
          <year>2012</year>
<volume>19</volume>
<fpage>3907</fpage>
<lpage>3921</lpage>
<pub-id pub-id-type="doi">10.2174/092986712802002464</pub-id>
<pub-id pub-id-type="pmid">22788767</pub-id>
</element-citation>
</ref>
<ref id="B94-cancers-12-00604">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rush</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Moritz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Goss</surname>
<given-names>V.L.</given-names>
</name>
<name>
<surname>Spek</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zha</surname>
<given-names>X.M.</given-names>
</name>
<name>
<surname>Polakiewicz</surname>
<given-names>R.D.</given-names>
</name>
<name>
<surname>Comb</surname>
<given-names>M.J.</given-names>
</name>
</person-group>
<article-title>Immunoaffinity profiling of tyrosine phosphorylation in cancer cells</article-title>
<source/>Nat. Biotechnol.
          <year>2005</year>
<volume>23</volume>
<fpage>94</fpage>
<lpage>101</lpage>
<pub-id pub-id-type="doi">10.1038/nbt1046</pub-id>
<pub-id pub-id-type="pmid">15592455</pub-id>
</element-citation>
</ref>
<ref id="B95-cancers-12-00604">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ashworth</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lord</surname>
<given-names>C.J.</given-names>
</name>
</person-group>
<article-title>Synthetic lethal therapies for cancer: What’s next after PARP inhibitors?</article-title>
<source/>Nat. Rev. Clin. Oncol.
          <year>2018</year>
<volume>15</volume>
<fpage>564</fpage>
<lpage>576</lpage>
<pub-id pub-id-type="doi">10.1038/s41571-018-0055-6</pub-id>
<pub-id pub-id-type="pmid">29955114</pub-id>
</element-citation>
</ref>
<ref id="B96-cancers-12-00604">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Aksoy</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Dogrusoz</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Dresdner</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gross</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Sumer</surname>
<given-names>S.O.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jacobsen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sinha</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Larsson</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal</article-title>
<source/>Sci. Signal.
          <year>2013</year>
<volume>6</volume>
<fpage>pl1</fpage>
<pub-id pub-id-type="doi">10.1126/scisignal.2004088</pub-id>
<pub-id pub-id-type="pmid">23550210</pub-id>
</element-citation>
</ref>
<ref id="B97-cancers-12-00604">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bradley</surname>
<given-names>W.E.</given-names>
</name>
<name>
<surname>Raelson</surname>
<given-names>J.V.</given-names>
</name>
<name>
<surname>Dubois</surname>
<given-names>D.Y.</given-names>
</name>
<name>
<surname>Godin</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Fournier</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Prive</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Allard</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Pinchuk</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Lapalme</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Paulussen</surname>
<given-names>R.J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Hotspots of large rare deletions in the human genome</article-title>
<source/>PLoS ONE
          <year>2010</year>
<volume>5</volume>
<elocation-id>e9401</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0009401</pub-id>
<pub-id pub-id-type="pmid">20195527</pub-id>
</element-citation>
</ref>
<ref id="B98-cancers-12-00604">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kadota</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Abnet</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Freedman</surname>
<given-names>N.D.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H.H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genomic landscape of somatic alterations in esophageal squamous cell carcinoma and gastric cancer</article-title>
<source/>Cancer Res.
          <year>2016</year>
<volume>76</volume>
<fpage>1714</fpage>
<lpage>1723</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-0338</pub-id>
<pub-id pub-id-type="pmid">26857264</pub-id>
</element-citation>
</ref>
<ref id="B99-cancers-12-00604">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Imagama</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Abe</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hayakawa</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Katsumi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Emi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kiyoi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Naoe</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>LRP16 is fused to RUNX1 in monocytic leukemia cell line with t(11;21)(q13;q22)</article-title>
<source/>Eur. J. Haematol.
          <year>2007</year>
<volume>79</volume>
<fpage>25</fpage>
<lpage>31</lpage>
<pub-id pub-id-type="doi">10.1111/j.1600-0609.2007.00858.x</pub-id>
<pub-id pub-id-type="pmid">17532767</pub-id>
</element-citation>
</ref>
<ref id="B100-cancers-12-00604">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Identification of novel fusion transcripts in undifferentiated pleomorphic sarcomas by transcriptome sequencing</article-title>
<source/>Cancer Genom. Proteom.
          <year>2019</year>
<volume>16</volume>
<fpage>399</fpage>
<lpage>408</lpage>
<pub-id pub-id-type="doi">10.21873/cgp.20144</pub-id>
</element-citation>
</ref>
<ref id="B101-cancers-12-00604">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meng</surname>
<given-names>Y.G.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>W.D.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Si</surname>
<given-names>Y.L.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z.Q.</given-names>
</name>
<name>
<surname>Mu</surname>
<given-names>Y.M.</given-names>
</name>
</person-group>
<article-title>Induction of the LRP16 gene by estrogen promotes the invasive growth of Ishikawa human endometrial cancer cells through the downregulation of E-cadherin</article-title>
<source/>Cell Res.
          <year>2007</year>
<volume>17</volume>
<fpage>869</fpage>
<lpage>880</lpage>
<pub-id pub-id-type="doi">10.1038/cr.2007.79</pub-id>
<pub-id pub-id-type="pmid">17893710</pub-id>
</element-citation>
</ref>
<ref id="B102-cancers-12-00604">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>A.J.</given-names>
</name>
</person-group>
<article-title>MitoMiner v4.0: An updated database of mitochondrial localization evidence, phenotypes and diseases</article-title>
<source/>Nucleic Acids Res.
          <year>2019</year>
<volume>47</volume>
<fpage>D1225</fpage>
<lpage>D1228</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gky1072</pub-id>
<pub-id pub-id-type="pmid">30398659</pub-id>
</element-citation>
</ref>
<ref id="B103-cancers-12-00604">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jing</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>LRP16 prevents hepatocellular carcinoma progression through regulation of Wnt/β-catenin signaling</article-title>
<source/>J. Mol. Med.
          <year>2018</year>
<volume>96</volume>
<fpage>547</fpage>
<lpage>558</lpage>
<pub-id pub-id-type="doi">10.1007/s00109-018-1639-4</pub-id>
<pub-id pub-id-type="pmid">29748698</pub-id>
</element-citation>
</ref>
<ref id="B104-cancers-12-00604">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Aberrant LRP16 protein expression in primary neuroendocrine lung tumors</article-title>
<source/>Int. J. Clin. Exp. Pathol.
          <year>2015</year>
<volume>8</volume>
<fpage>6560</fpage>
<lpage>6565</lpage>
<pub-id pub-id-type="pmid">26261536</pub-id>
</element-citation>
</ref>
<ref id="B105-cancers-12-00604">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mo</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Jiao</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Leukemia-Related protein 16 (LRP16) promotes tumor growth and metastasis in pancreatic cancer</article-title>
<source/>OncoTargets Ther.
          <year>2018</year>
<volume>11</volume>
<fpage>1215</fpage>
<lpage>1222</lpage>
<pub-id pub-id-type="doi">10.2147/OTT.S157914</pub-id>
</element-citation>
</ref>
<ref id="B106-cancers-12-00604">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xi</surname>
<given-names>H.Q.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>W.D.</given-names>
</name>
</person-group>
<article-title>Clinicopathological significance and prognostic value of LRP16 expression in colorectal carcinoma</article-title>
<source/>World J. Gastroenterol.
          <year>2010</year>
<volume>16</volume>
<fpage>1644</fpage>
<lpage>1648</lpage>
<pub-id pub-id-type="doi">10.3748/wjg.v16.i13.1644</pub-id>
<pub-id pub-id-type="pmid">20355243</pub-id>
</element-citation>
</ref>
<ref id="B107-cancers-12-00604">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y.Z.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>W.D.</given-names>
</name>
</person-group>
<article-title>Clinicopathological significance of LRP16 protein in 336 gastric carcinoma patients</article-title>
<source/>World J. Gastroenterol.
          <year>2009</year>
<volume>15</volume>
<fpage>4833</fpage>
<lpage>4837</lpage>
<pub-id pub-id-type="doi">10.3748/wjg.15.4833</pub-id>
<pub-id pub-id-type="pmid">19824120</pub-id>
</element-citation>
</ref>
<ref id="B108-cancers-12-00604">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yao</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Qiao</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.T.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>C.H.</given-names>
</name>
</person-group>
<article-title>Correlation between expression of LRP16, Ki67 and EGFR and breast cancer clinical pathologic factors and prognosis</article-title>
<source/>Eur. Rev. Med. Pharmacol. Sci.
          <year>2017</year>
<volume>21</volume>
<fpage>47</fpage>
<lpage>51</lpage>
<pub-id pub-id-type="pmid">28745792</pub-id>
</element-citation>
</ref>
<ref id="B109-cancers-12-00604">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lo Re</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Mazza</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Vinciguerra</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Mono-ADP-ribosylhydrolase MACROD2 is dispensable for murine responses to metabolic and genotoxic insults</article-title>
<source/>Front. Genet.
          <year>2018</year>
<volume>9</volume>
<fpage>654</fpage>
<pub-id pub-id-type="doi">10.3389/fgene.2018.00654</pub-id>
<pub-id pub-id-type="pmid">30619475</pub-id>
</element-citation>
</ref>
<ref id="B110-cancers-12-00604">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mohseni</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cidado</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Croessmann</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cravero</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Cimino-Mathews</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>H.Y.</given-names>
</name>
<name>
<surname>Scharpf</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zabransky</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Abukhdeir</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Garay</surname>
<given-names>J.P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2014</year>
<volume>111</volume>
<fpage>17606</fpage>
<lpage>17611</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1408650111</pub-id>
<pub-id pub-id-type="pmid">25422431</pub-id>
</element-citation>
</ref>
<ref id="B111-cancers-12-00604">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sakthianandeswaren</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Parsons</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Mouradov</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>MacKinnon</surname>
<given-names>R.N.</given-names>
</name>
<name>
<surname>Catimel</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Palmieri</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Love</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Jorissen</surname>
<given-names>R.N.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>MACROD2 haploinsufficiency impairs catalytic activity of PARP1 and promotes chromosome instability and growth of intestinal tumors</article-title>
<source/>Cancer Discov.
          <year>2018</year>
<volume>8</volume>
<fpage>988</fpage>
<lpage>1005</lpage>
<pub-id pub-id-type="doi">10.1158/2159-8290.CD-17-0909</pub-id>
<pub-id pub-id-type="pmid">29880585</pub-id>
</element-citation>
</ref>
<ref id="B112-cancers-12-00604">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sakthianandeswaren</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Parsons</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Mouradov</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sieber</surname>
<given-names>O.M.</given-names>
</name>
</person-group>
<article-title>MACROD2 deletions cause impaired PARP1 activity and chromosome instability in colorectal cancer</article-title>
<source/>Oncotarget
          <year>2018</year>
<volume>9</volume>
<fpage>33056</fpage>
<lpage>33058</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.25887</pub-id>
<pub-id pub-id-type="pmid">30237848</pub-id>
</element-citation>
</ref>
<ref id="B113-cancers-12-00604">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van den Broek</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>den Uil</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Coupe</surname>
<given-names>V.M.H.</given-names>
</name>
<name>
<surname>Delis-van Diemen</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Bolijn</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Bril</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Stockmann</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>van Grieken</surname>
<given-names>N.C.T.</given-names>
</name>
<name>
<surname>Meijer</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Fijneman</surname>
<given-names>R.J.A.</given-names>
</name>
</person-group>
<article-title>MACROD2 expression predicts response to 5-FU-based chemotherapy in stage III colon cancer</article-title>
<source/>Oncotarget
          <year>2018</year>
<volume>9</volume>
<fpage>29445</fpage>
<lpage>29452</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.25655</pub-id>
<pub-id pub-id-type="pmid">30034629</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="cancers-12-00604-f001" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>Overview of the <italic>MACROD1</italic>, <italic>MACROD2</italic>, and <italic>OARD1</italic> gene structure.</p>
</caption>
<graphic xlink:href="cancers-12-00604-g001"></graphic>
</fig>
<table-wrap id="cancers-12-00604-t001" orientation="portrait" position="float">
<object-id pub-id-type="pii">cancers-12-00604-t001_Table 1</object-id>
<label>Table 1</label>
<caption>
<p>Summary of nomenclature, expression, and localisation data of MACROD1, MACROD2, and TARG1.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Protein Name</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Alternative Names</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Gene Name</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">MW Predicted</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">MW Observed</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Intracellular Localisation</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Expression</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Regulation</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">MACROD1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">LRP16</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>MACROD1</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">35.5 kDa</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">27 kDa* [<xref ref-type="bibr" rid="B70-cancers-12-00604">70</xref>,<xref ref-type="bibr" rid="B71-cancers-12-00604">71</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mitochondrial [<xref ref-type="bibr" rid="B40-cancers-12-00604">40</xref>,<xref ref-type="bibr" rid="B70-cancers-12-00604">70</xref>,<xref ref-type="bibr" rid="B71-cancers-12-00604">71</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Ubiquitous expression, enriched in skeletal muscle [<xref ref-type="bibr" rid="B70-cancers-12-00604">70</xref>,<xref ref-type="bibr" rid="B71-cancers-12-00604">71</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">mRNA expression is induced by oestrogen [<xref ref-type="bibr" rid="B72-cancers-12-00604">72</xref>,<xref ref-type="bibr" rid="B73-cancers-12-00604">73</xref>,<xref ref-type="bibr" rid="B74-cancers-12-00604">74</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">MACROD2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">C20orf133</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>MACROD2</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">47 kDa</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">50 kDa [<xref ref-type="bibr" rid="B70-cancers-12-00604">70</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Diffuse nuclear, cytoplasmic [<xref ref-type="bibr" rid="B70-cancers-12-00604">70</xref>,<xref ref-type="bibr" rid="B75-cancers-12-00604">75</xref>] </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">So far detected only in the brain [<xref ref-type="bibr" rid="B70-cancers-12-00604">70</xref>,<xref ref-type="bibr" rid="B76-cancers-12-00604">76</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Phosphorylation by ATM upon DNA damage induces translocation to cytoplasm [<xref ref-type="bibr" rid="B75-cancers-12-00604">75</xref>] </td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">TARG1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">C6orf130</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>OARD1</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">17 kDa</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">17 kDa [<xref ref-type="bibr" rid="B14-cancers-12-00604">14</xref>,<xref ref-type="bibr" rid="B70-cancers-12-00604">70</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Nuclear, nucleolar, stress granular [<xref ref-type="bibr" rid="B14-cancers-12-00604">14</xref>,<xref ref-type="bibr" rid="B45-cancers-12-00604">45</xref>,<xref ref-type="bibr" rid="B70-cancers-12-00604">70</xref>] </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Ubiquitous expression [<xref ref-type="bibr" rid="B70-cancers-12-00604">70</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Leaves nucleoli upon DNA damage [<xref ref-type="bibr" rid="B14-cancers-12-00604">14</xref>]</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>* The predicted molecular weight of MACROD1 is 35 kDa. However, due to cleavage of the N-terminus upon translocation into mitochondria, the protein detected in western blotting (WB) is smaller [<xref ref-type="bibr" rid="B70-cancers-12-00604">70</xref>].</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="cancers-12-00604-t002" orientation="portrait" position="float">
<object-id pub-id-type="pii">cancers-12-00604-t002_Table 2</object-id>
<label>Table 2</label>
<caption>
<p>Summary of studies studying the effect of MACROD1 and MACROD2 protein levels on cell and/or tumour growth.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Cancer Tissue</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Protein</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Expression</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Effect/Prognosis</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Antibody Used</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Neuroendocrine lung tumours</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">MACROD1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Elevated</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Poorer survival</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Monoclonal rabbit antibody against LRP16 <break></break>Not further specified or validated</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B104-cancers-12-00604">104</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Hepatocellular carcinoma</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">MACROD1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Overexpressed: N- or C- tag not specified</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Lower cell and tumour growth</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Santa Cruz goat polyclonal<break></break>This antibody is not available anymore. Whole blots are not shown. It was not validated with siRNA</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B103-cancers-12-00604">103</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Pancreatic carcinoma</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">MACROD1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Overexpressed: N- or C- tag not specified</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Higher cell and tumour growth</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Abcam rabbit polyclonal<break></break>This antibody recognises multiple bands in WB and is thus not suitable for IHC/IF</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B105-cancers-12-00604">105</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Colorectal carcinoma</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">MACROD1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Elevated</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Poorer survival</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Polyclonal rabbit antibody generated by the authors’ institute<break></break>Not further specified or validated</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B106-cancers-12-00604">106</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gastric carcinoma</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">MACROD1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Elevated</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Poorer survival </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Polyclonal rabbit antibody generated by the authors’ institute<break></break>Not further specified or validated</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B107-cancers-12-00604">107</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Breast cancer</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">MACROD1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">MACROD1 expression quantified as either positive or negative</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">MACROD1 expression was higher in patients with advanced stages </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">LRP16 rabbit anti-human antibody, source not given<break></break>Not further specified or validated</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B108-cancers-12-00604">108</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Endometrial cancer</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">MACROD1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Overexpressed</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">No effect on proliferation but enhanced invasion</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Antiserum generated in rabbits against amino acids 83-324</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B101-cancers-12-00604">101</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Breast cancer</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">MACROD1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Overexpression</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased proliferation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Not specified</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B74-cancers-12-00604">74</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Colorectal carcinoma</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">MACROD1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Non-tagged and N-terminal flag-tagged overexpression</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Confers resistance to chemotherapeutics</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Antibody used for IHC and WB not specified, recognises bands at ±35 and ±45 kDa</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B88-cancers-12-00604">88</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Tumours induced in mice by sublethal irradiation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">MACROD2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Knockout mice</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">No difference between wildtype and MacroD2<sup>-/-</sup></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Thermofisher PA5-45950 <break></break>This antibody recognises bands at ±38 kDa and ±22 kDa</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B109-cancers-12-00604">109</xref>]</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>